

Alessandro Rambaldi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4186287/alessandro-rambaldi-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

899
papers

36,638
citations

104
h-index

165
g-index

941
ext. papers

42,272
ext. citations

4.9
avg, IF

6.61
L-index

#	Paper	IF	Citations
899	Second versus first wave of COVID-19 in patients with MPN.. <i>Leukemia</i> , 2022 ,	10.7	2
898	Myeloid Malignancies 2022 , 97-103		
897	Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous positive myeloid sarcoma and acute B-lymphoblastic leukemia.. <i>Clinical Case Reports (discontinued)</i> , 2022 , 10, e05212	0.7	1
896	Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	0
895	Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey.. <i>Frontiers in Oncology</i> , 2022 , 12, 828072	5.3	
894	Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102389	2.2	5
893	High inter-follicular spatial co-localisation of CD8+FOXP3+ with CD4+CD8+ cells predicts favourable outcome in follicular lymphoma.. <i>Hematological Oncology</i> , 2022 ,	1.3	1
892	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021 , 35, 3444-3454	10.7	11
891	Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial. <i>Blood</i> , 2021 , 138, 2443-2443	2.2	1
890	A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1). <i>Blood</i> , 2021 , 138, 385-385	2.2	2
889	A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2021 , 138, 2436-2436	2.2	
888	The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis. <i>Blood</i> , 2021 , 138, 236-236	2.2	0
887	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of ERNEST Study. <i>Blood Advances</i> , 2021 ,	7.8	10
886	Second Versus First Wave of COVID-19 in Patients with MPN. <i>Blood</i> , 2021 , 138, 315-315	2.2	
885	Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT. <i>Blood</i> , 2021 , 138, 472-472	2.2	0
884	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. <i>Haematologica</i> , 2021 , 106, 2578-2587	6.6	7
883	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. <i>Hematological Oncology</i> , 2021 ,	1.3	2

882	A three-gene signature based on , and improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021 , 106, 2405-2416	6.6	4
881	Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. <i>European Journal of Cancer</i> , 2021 , 146, 107-114	7.5	13
880	Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. <i>Blood Cancer Journal</i> , 2021 , 11, 53	7	5
879	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. <i>Blood Advances</i> , 2021 , 5, 1452-1462	7.8	1
878	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. <i>Lancet Haematology</i> , 2021 , 8, e175-e184	14.6	24
877	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1944-1952	4.4	1
876	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1223-1233	2.2	25
875	MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL. <i>Cancers</i> , 2021 , 13,	6.6	2
874	Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2280-2283	4.4	
873	Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. <i>Leukemia</i> , 2021 , 35, 2710-2714	10.7	13
872	Long-term follow-up of recovered MPN patients with COVID-19. <i>Blood Cancer Journal</i> , 2021 , 11, 115	7	6
871	Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. <i>Blood</i> , 2021 , 138, 2290-2293	2.2	3
870	Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. <i>British Journal of Haematology</i> , 2021 , 195, 244-248	4.5	7
869	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. <i>Haematologica</i> , 2021 , 106, 1559-1568	6.6	20
868	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. <i>Bone Marrow Transplantation</i> , 2021 , 56, 20-29	4.4	0
867	Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 210-217	4.4	4
866	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021 , 56, 622-634	4.4	2
865	Splenectomy before allogeneic hematopoietic stem-cell transplantation for myelofibrosis: Tumor burden matters!. <i>American Journal of Hematology</i> , 2021 , 96, 12-13	7.1	0

864	Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. <i>Nature Immunology</i> , 2021 , 22, 19-24	19.1	47
863	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and		1
862	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 481-491	4.4	0
861	Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1490-1496	1.9	19
860	CD123 Is Consistently Expressed on -Mutated AML Cells. <i>Cancers</i> , 2021 , 13,	6.6	6
859	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. <i>Leukemia</i> , 2021 , 35, 485-493	10.7	45
858	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021 , 384, 705-716	59.2	287
857	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021 , 11, 21	7	14
856	Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies. <i>Journal of Clinical Oncology</i> , 2021 , 39, 444-455	2.2	8
855	Bergamo and Covid-19: How the Dark Can Turn to Light. <i>Frontiers in Medicine</i> , 2021 , 8, 609440	4.9	6
854	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2606-2609	4.4	1
853	Skip pattern approach toward the early access of innovative anticancer drugs. <i>ESMO Open</i> , 2021 , 6, 100227		0
852	NOVEL NPM1 EXON 5 MUTATIONS AND GENE FUSIONS LEADING TO ABERRANT CYTOPLASMIC NUCLEOPHOSMIN IN AML. <i>Blood</i> , 2021 ,	2.2	5
851	Concurrent Diagnosis of Acute Myeloid Leukemia and Symptomatic COVID-19 Infection: a Case Report Successfully Treated with Azacitidine-Venetoclax Combination. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021 , 13, e2021057	3.2	1
850	Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs. <i>Blood</i> , 2020 , 135, 1560-1573	2.2	35
849	An agenda for future research projects in polycythemia vera and essential thrombocythemia. <i>Haematologica</i> , 2020 , 105, 1999-2003	6.6	3
848	Impact of detectable measurable residual disease on umbilical cord blood transplantation. <i>American Journal of Hematology</i> , 2020 , 95, 1057-1065	7.1	4
847	Capture-based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes. <i>Cancers</i> , 2020 , 12,	6.6	6

846	Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2103-2112	1.9	28
845	Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper. <i>Cancer Medicine</i> , 2020 , 9, 2960-2970	4.8	5
844	Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1580-1587	4.4	9
843	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020 , 34, 2354-2363	10.7	118
842	Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy. <i>Hematological Oncology</i> , 2020 , 38, 501-508	1.3	7
841	Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. <i>Leukemia</i> , 2020 , 34, 2234-2237	10.7	19
840	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1093-1102	4.4	30
839	Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study. <i>American Journal of Hematology</i> , 2020 , 95, 953-959	7.1	4
838	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. <i>Blood Advances</i> , 2020 , 4, 1082-1092	7.8	21
837	Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity. <i>Blood</i> , 2020 , 136, 34-34	2.2	
836	Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse. <i>Blood</i> , 2020 , 136, 38-39	2.2	1
835	Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6021-6033	15.9	31
834	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. <i>Lancet Haematology</i> , 2020 , 7, e28-e39	14.6	40
833	Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , 2020 , 95, E1-E3	7.1	3
832	Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. <i>Cancer</i> , 2020 , 126, 304-310	6.4	28
831	Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 698-703	4.7	7
830	Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival. <i>British Journal of Haematology</i> , 2020 , 188, 550-559	4.5	5
829	Second cancers in MPN: Survival analysis from an international study. <i>American Journal of Hematology</i> , 2020 , 95, 295-301	7.1	20

828	Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. <i>New England Journal of Medicine</i> , 2020 , 383, 1613-1623	59.2	103
827	A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. <i>Blood Cancer Journal</i> , 2020 , 10, 100	7	3
826	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. <i>Lancet Haematology</i> , 2020 , 7, e861-e873	14.6	19
825	The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial. <i>Cancer Medicine</i> , 2020 , 9, 8735-8746	4.8	6
824	Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07. <i>Blood Cancer Journal</i> , 2020 , 10, 119	7	10
823	Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. <i>Immunobiology</i> , 2020 , 225, 152001	3.4	64
822	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020 , 9, 6565-6575	4.8	11
821	Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3905-3913	2.2	15
820	High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). <i>Cancers</i> , 2020 , 12,	6.6	2
819	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020 , 34, 914-918	10.7	26
818	Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020 , 4, 1518-1525	7.8	7
817	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020 , 135, 381-386	2.2	14
816	Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. <i>Blood Advances</i> , 2020 , 4, 301-311	7.8	6
815	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood</i> , 2019 , 134, 1498-1509	2.2	80
814	Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with Positive Acute Myeloid Leukemia. <i>Cancers</i> , 2019 , 11,	6.6	16
813	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. <i>Cancer Medicine</i> , 2019 , 8, 4089-4092	4.8	10
812	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 781-794	21.7	150
811	Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1498-1504	4.7	25

810	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. <i>Leukemia Research</i> , 2019 , 81, 88-94	2.7	6
809	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. <i>Haematologica</i> , 2019 , 104, 2241-2248	6.6	6
808	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019 , 25, 603-611	50.5	136
807	Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1387-1394	4.7	1
806	CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL. <i>Hematological Oncology</i> , 2019 , 37, 147-148	1.3	2
805	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <i>Journal of Clinical Medicine</i> , 2019 , 8, 2000-2007	4.7	14
804	Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. <i>Lancet Infectious Diseases</i> , 2019 , 19, 1001-1012	25.5	16
803	A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. <i>Leukemia</i> , 2019 , 33, 2974-2978	10.7	13
802	MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. <i>Hematological Oncology</i> , 2019 , 37, 181-182	1.3	
801	Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2019 , 5, 1739-1748	13.4	41
800	BRENTUXIMAB-VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST-LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL). <i>Hematological Oncology</i> , 2019 , 37, 292-293	1.3	2
799	A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML. <i>Blood</i> , 2019 , 134, 3855-3855	2.2	2
798	Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06. <i>Blood</i> , 2019 , 134, 1443-1443	2.2	1
797	Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings. <i>Blood</i> , 2019 , 134, 2943-2943	2.2	4
796	Outcomes Following Second Allogeneic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2019 , 134, 698-698	2.2	1
795	Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2019 , 134, 200-200	2.2	3
794	Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial. <i>Blood</i> , 2019 , 134, 740-740	2.2	23
793	PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE. <i>HemaSphere</i> , 2019 , 3, 65-66	0.3	

792	PF436 GMP MANUFACTURING OF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) CYTOKINE INDUCED KILLER (CIK) CELLS WITH SLEEPING BEAUTY (SB) TRANSPOSON FOR ADOPTIVE IMMUNOTHERAPY. <i>HemaSphere</i> , 2019 , 3, 171	0.3	
791	PF435 A FLEXIBLE THERAPEUTIC STRATEGY FOR LEUKEMIA USING EX-VIVO EXPANDED T CELLS COMBINED WITH BISPECIFIC ANTIBODIES. <i>HemaSphere</i> , 2019 , 3, 170-171	0.3	
790	PS1257 LYMPHOCYTE TO MONOCYTE RATIO (LMR) PREDICTS PROGRESSION-FREE SURVIVAL INDEPENDENTLY FROM FLIPI AND IS USEFUL IN IDENTIFYING PATIENTS WITH EARLY DISEASE PROGRESSION. <i>HemaSphere</i> , 2019 , 3, 574-575	0.3	
789	Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. <i>Blood</i> , 2019 , 134, 2627-2627	2.2	1
788	Outcome of Two Loci Mismatched (B/8) Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia: ALWP of the EBMT Study. <i>Blood</i> , 2019 , 134, 4604-4604	2.2	
787	Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. <i>Blood</i> , 2019 , 134, 2624-2624	2.2	
786	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. <i>Blood</i> , 2019 , 134, 2946-2946	2.2	
785	Evaluation and Counseling of Candidates 2019 , 77-86		3
784	PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT. <i>HemaSphere</i> , 2019 , 3, 671	0.3	2
783	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019 , 24, 337-348	2.2	33
782	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <i>Blood Advances</i> , 2019 , 3, 1103-1117	7.8	11
781	Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. <i>Blood</i> , 2019 , 134, 1708-1711	2.2	8
780	S113 GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA. <i>HemaSphere</i> , 2019 , 3, 8-9	0.3	
779	INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT. <i>Hematological Oncology</i> , 2019 , 37, 77-78	1.3	
778	AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY. <i>Hematological Oncology</i> , 2019 , 37, 98-99	1.3	1
777	INTEGRATING TUMOR- AND MICROENVIRONMENT-REFLECTING GENES IN A UNIQUE AND ROUTINE-APPLICABLE ASSAY FOR ACCURATE RISK PREDICTION IN DLBCL. <i>Hematological Oncology</i> , 2019 , 37, 139-140	1.3	
776	S1617 A DASATINIB-BLINATUMOMAB COMBINATION FOR THE FRONT-LINE TREATMENT OF ADULT PH+ ALL PATIENTS. PRELIMINARY RESULTS OF THE GIMEMA LAL2116 D-ALBA TRIAL; ON BEHALF OF GIMEMA ACUTE LEUKEMIA WORKING PARTY. <i>HemaSphere</i> , 2019 , 3, 746	0.3	5
775	Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia. <i>Genes</i> , 2019 , 10,	4.2	14

774	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 114-120	4.7	14
773	Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 932-940	4.7	14
772	Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. <i>Journal of Internal Medicine</i> , 2019 , 285, 446-454	10.8	3
771	Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2019 , 106, 212-219	7.5	6
770	IDH1-R132 changes vary according to NPM1 and other mutations status in AML. <i>Leukemia</i> , 2019 , 33, 1043-1047	10.7	9
769	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019 , 51, 296-307	36.3	189
768	Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis. <i>American Journal of Hematology</i> , 2019 , 94, E11-E13	7.1	1
767	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 229-240	40	283
766	Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. <i>American Journal of Hematology</i> , 2019 , 94, 231-239	7.1	7
765	Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. <i>European Journal of Haematology</i> , 2018 , 101, 78-85	3.8	3
764	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. <i>Haematologica</i> , 2018 , 103, e392-e394	6.6	20
763	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , 2018 , 32, 1200-1210	10.7	68
762	The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. <i>American Journal of Hematology</i> , 2018 , 93, 615-622	7.1	5
761	Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMMDR study. <i>Bone Marrow Transplantation</i> , 2018 , 53, 291-294	4.4	3
760	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. <i>Leukemia Research</i> , 2018 , 69, 100-102	2.7	5
759	Phase I study of the heparanase inhibitor roneparstat: an innovative approach for multiple myeloma therapy. <i>Haematologica</i> , 2018 , 103, e469-e472	6.6	65
758	Risk factors associated with development and mortality by invasive fungal diseases in pediatric allogeneic stem cell transplantation. A pediatric subgroup analysis of data from a prospective study of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2018 , 53, 1193-1197	4.4	5
757	TP53 in adult acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 778-789	1.9	5

756	Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. <i>Leukemia</i> , 2018 , 32, 438-449	10.7	15
755	Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19 tumors. <i>Cytotherapy</i> , 2018 , 20, 1077-1088	4.8	3
754	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. <i>Blood Cancer Journal</i> , 2018 , 8, 49	7	21
753	Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1). <i>Blood</i> , 2018 , 132, 690-690	2.2	19
752	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2018 , 132, 3032-3032	2.2	6
751	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). <i>Blood</i> , 2018 , 132, 577-577	2.2	32
750	Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 400-400	2.2	7
749	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018 , 132, 922-922	2.2	2
748	Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study. <i>Blood</i> , 2018 , 132, 3404-3404	2.2	1
747	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. <i>Blood</i> , 2018 , 132, 43-43	2.2	6
746	Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy. <i>Oncotarget</i> , 2018 , 9, 9766-9775	3.3	7
745	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 565-565	2.2	1
744	High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt. <i>Blood</i> , 2018 , 132, 4642-4642	2.2	
743	Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications. <i>Blood</i> , 2018 , 132, 196-196	2.2	
742	Clinical Impact of an Accurate Genetic Characterization of Older Acute Myeloid Leukemia Patients: A Report from the Northern Italy Leukemia Group (NILG) Randomized Trial 02/06. <i>Blood</i> , 2018 , 132, 434-434	2.2	34
741	Permissive HLA-DPB1 Mismatch and Survival after Unrelated Donor Allogeneic Stem Cell Transplantation for Hematological Malignancies: A Comparative Analysis of Different Immunogenetic Models on 422 Patients from GITMO and IBMDR. <i>Blood</i> , 2018 , 132, 482-482	2.2	
740	Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2018 , 132, 2143-2143	2.2	
739	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol. <i>Blood</i> , 2018 , 132, 2934-2934	2.2	

738	Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. <i>Blood</i> , 2018 , 132, 3039-3039	2.2	
737	Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. <i>Journal of Internal Medicine</i> , 2018 , 283, 371-379	10.8	15
736	Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance. <i>Cytotherapy</i> , 2018 , 20, 262-270	4.8	13
735	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 507-513	4.7	5
734	Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2018 , 78, 1097-1109	10.1	15
733	Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia. <i>Handbook of Experimental Pharmacology</i> , 2018 , 249, 231-250	3.2	10
732	Ruxolitinib-associated infections: A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2018 , 93, 339-347	7.1	113
731	Reply to H.J.A. Adams et al and C. Mesguich et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2125-2126	2.2	2
730	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018 , 36, 310-318	2.2	224
729	Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 151-159	2.2	125
728	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. <i>Blood Cancer Journal</i> , 2018 , 8, 89	7	8
727	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1530-1542	21.7	59
726	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. <i>Annals of Oncology</i> , 2018 , 29, 2363-2370	10.3	47
725	Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2018 , 78, 5793-5807	10.1	9
724	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 110	22.4	29
723	Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2018 , 391, 2116-2127	40	62
722	Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2017 , 52, 955-961	4.4	16
721	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. <i>British Journal of Cancer</i> , 2017 , 116, 335-343	8.7	17

720	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. <i>Haematologica</i> , 2017 , 102, 160-167	6.6	32
719	No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. <i>Haematologica</i> , 2017 , 102, e219-e221	6.6	16
718	Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 54	22.4	30
717	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017 , 376, 836-847	59.2	978
716	-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. <i>Haematologica</i> , 2017 , 102, 529-540	6.6	36
715	Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort. <i>American Journal of Hematology</i> , 2017 , 92, 429-434	7.1	23
714	High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. <i>Journal of Clinical Oncology</i> , 2017 , 35, 394-401	2.2	227
713	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1102-1109	4.7	5
712	Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies. <i>Expert Review of Hematology</i> , 2017 , 10, 627-636	2.8	
711	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 821-836	5.4	3
710	Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1120-1125	4.4	6
709	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. <i>Leukemia</i> , 2017 , 31, 2726-2731	10.7	146
708	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. <i>Haematologica</i> , 2017 , 102, 85-93	6.6	29
707	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017 , 31, 2449-2457	10.7	26
706	Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <i>Annals of Oncology</i> , 2017 , 28, 1547-1553	10.3	36
705	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. <i>Blood</i> , 2017 , 129, 3227-3236	2.2	86
704	Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1225-1232	4.4	8
703	PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias. <i>Leukemia</i> , 2017 , 31, 1975-1986	10.7	8

702	Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1795-1802	2.2	264
701	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. <i>Blood</i> , 2017 , 130, 1768-1771	2.2	45
700	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. <i>Nature Communications</i> , 2017 , 8, 593	17.4	104
699	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 2070-2078	4.7	35
698	Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17S, S2-S9	2	13
697	TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF A PHASE 1 STUDY. <i>Hematological Oncology</i> , 2017 , 35, 72-74	1.3	3
696	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. <i>Leukemia Research</i> , 2017 , 63, 34-40	2.7	12
695	Inflammation and myeloproliferative neoplasms. <i>Journal of Autoimmunity</i> , 2017 , 85, 58-63	15.5	66
694	Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 935-940	9.5	56
693	Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2017 , 52, 163-166	4.4	15
692	The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. <i>American Journal of Hematology</i> , 2017 , 92, E5-E6	7.1	32
691	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 605-612	2.2	220
690	The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. <i>Bone Marrow Transplantation</i> , 2017 , 52, 357-362	4.4	11
689	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2017 , 92, 187-195	7.1	26
688	Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients. <i>Leukemia</i> , 2017 , 31, 970-973	10.7	27
687	Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2017 , 52, 238-244	4.4	8
686	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1884-1896	11.6	63
685	RAR α and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells. <i>Oncotarget</i> , 2017 , 8, 37041-37060	3.3	7

684	Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017 , 9, e2017010	3.3	7
683	Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1234-7	1.9	2
682	Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. <i>American Journal of Hematology</i> , 2016 , 91, 995-1001	7.1	30
681	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. <i>American Journal of Hematology</i> , 2016 , 91, 681-6	7.1	54
680	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. <i>International Journal of Cancer</i> , 2016 , 138, 1657-69	7.5	4
679	Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children. <i>Transplantation</i> , 2016 , 100, 437-45	1.8	11
678	PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. <i>Thrombosis Research</i> , 2016 , 140 Suppl 1, S183	8.2	1
677	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. <i>Journal of Clinical Oncology</i> , 2016 , 34, 151-9	2.2	42
676	Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT. <i>Annals of Oncology</i> , 2016 , 27, 1088-1094	10.3	25
675	Rabbit anti-thymocyte globulin to prevent GVHD. <i>Lancet Oncology, The</i> , 2016 , 17, 124-125	21.7	1
674	Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation. <i>Blood</i> , 2016 , 128, 1160-1160	2.2	5
673	Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016 , 128, 176-176	2.2	17
672	Health Related Quality of Life of Long-Term Survivors of Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Chemotherapy. <i>Blood</i> , 2016 , 128, 2415-2415	2.2	1
671	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. <i>Blood</i> , 2016 , 128, 3117-3117	2.2	4
670	A PHASE 1/2 Clinical Trial of Brentuximab-Vedotin and Bendamustine in Elderly Patients with Previously Untreated Advanced Hodgkin Lymphoma (HALO STUDY. NCT identifier : 02467946): Preliminary Report. <i>Blood</i> , 2016 , 128, 4154-4154	2.2	5
669	A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results. <i>Blood</i> , 2016 , 128, 4261-4261	2.2	4
668	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2016 , 128, 4271-4271	2.2	4
667	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2016 , 128, 479-479	2.2	20

666	Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. <i>Blood</i> , 2016 , 128, 624-624	2.2	7
665	JAK2V617F Mutation and Thrombosis History Are Determinants of Mean Platelet Volume (MPV) in Essential Thrombocythemia Patients. <i>Blood</i> , 2016 , 128, 2606-2606	2.2	
664	Autologous Versus Related Versus Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016 , 128, 2279-2279	2.2	
663	Tenascin-C Is Highly Expressed in T-Cell Non-Hodgkin Lymphomas and Represents an Attractive Target for Radioimmunotherapy. <i>Blood</i> , 2016 , 128, 4141-4141	2.2	1
662	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2016 , 128, 3467-3467	2.2	
661	Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group. <i>Blood</i> , 2016 , 128, 5463-5463	2.2	
660	Prediction of Allogeneic Stem Cell Transplantation Mortality in Patients with Acute Leukemia (AL) Using the AL- European Society for Blood and Marrow Transplantation (EBMT) Risk Score in the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) Data Set: A Study on Behalf of the AL Working Party (ALWP) of the EBMT and GITMO. <i>Blood</i> , 2016 , 128, 989-989	2.2	
659	Effects of Antiplatelet Treatment with Aspirin (ASA) on Platelet Reactivity in Patients with Essential Thrombocythemia. <i>Blood</i> , 2016 , 128, 4253-4253	2.2	
658	Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS). <i>Blood</i> , 2016 , 128, 3473-3473	2.2	
657	Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features. <i>Blood</i> , 2016 , 128, 5625-5625	2.2	
656	Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2016 , 128, 53-53	2.2	
655	Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group. <i>Blood</i> , 2016 , 128, 943-943	2.2	
654	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. <i>American Journal of Hematology</i> , 2016 , 91, 918-22	7.1	40
653	Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. <i>Haematologica</i> , 2016 , 101, e34-7	6.6	7
652	Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival. <i>Haematologica</i> , 2016 , 101, e245-8	6.6	18
651	Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia--Authors' reply. <i>Lancet Oncology</i> , 2016 , 17, e1-2	21.7	
650	PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN). <i>Thrombosis Research</i> , 2016 , 140 Suppl 1, S185-6	8.2	6
649	Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) Among Adults with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) Achieving Remission with Blinatumomab. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, S35-S36	4.7	2

648	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3627-3637	2.2	147
647	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4015-4022	2.2	49
646	Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1983-1987	4.7	58
645	Consensus recommendations for improvement of unmet clinical needs--the example of chronic graft-versus-host disease: a systematic review and meta-analysis. <i>Lancet Haematology</i> , 2015 , 2, e297-305	14.6	14
644	Management of carbapenem resistant <i>Klebsiella pneumoniae</i> infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. <i>Haematologica</i> , 2015 , 100, e373-6	6.6	38
643	Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015 , 100, 392-9	6.6	97
642	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 1525-1536	21.7	103
641	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. <i>Leukemia Research</i> , 2015 , 39, 1055-9	2.7	43
640	Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. <i>Leukemia</i> , 2015 , 29, 2126-33	10.7	171
639	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015 , 373, 1733-47	59.2	215
638	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1418-24	4.7	47
637	Progressione del plasmocitoma solitario dell'osso a livello mandibolare in mieloma multiplo. <i>Dental Cadmos</i> , 2015 , 83, 570-576	2.3	
636	CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. <i>Leukemia</i> , 2015 , 29, 1209-10	10.7	21
635	Infections by carbapenem-resistant <i>Klebsiella pneumoniae</i> in SCT recipients: a nationwide retrospective survey from Italy. <i>Bone Marrow Transplantation</i> , 2015 , 50, 282-8	4.4	108
634	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 75-85	2	24
633	Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. <i>Leukemia</i> , 2015 , 29, 1-10	10.7	46
632	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. <i>American Journal of Hematology</i> , 2015 , 90, 434-7	7.1	11
631	Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. <i>Blood Cancer Journal</i> , 2015 , 5, e369	7	123

630	White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. <i>Blood</i> , 2015 , 126, 560-1	2.2	60
629	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2015 , 100, e501-4	6.6	18
628	Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. <i>Haematologica</i> , 2015 , 100, 786-93	6.6	19
627	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2015 , 2, 2101-9	8.8	28
626	Second allogeneic stem cell transplant for aplastic anaemia: a retrospective study by the Severe Aplastic Anaemia Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2015 , 171, 606-14	4.5	18
625	Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: successes and hurdles. <i>Current Opinion in Organ Transplantation</i> , 2015 , 20, 72-8	2.5	45
624	Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. <i>Neurology</i> , 2015 , 84, 981-8	6.5	155
623	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the	22.4	33
622	Mobilization of peripheral blood hematopoietic stem cells by granulocyte-colony stimulating factor and plerixafor in patients with cardiac AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> 2015 , 22, 259-60	2.7	2
621	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2015 , 16, 57-66	21.7	832
620	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015 , 26, 185-192	10.3	48
619	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. <i>Haematologica</i> , 2015 , 100, 77-86	6.6	115
618	Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology. <i>Oncoscience</i> , 2015 , 2, 50-8	0.8	14
617	High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. <i>Blood</i> , 2015 , 126, 2618-2618	2.2	4
616	Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm. <i>Blood</i> , 2015 , 126, 2803-2803	2.2	2
615	A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease. <i>Blood</i> , 2015 , 126, 3160-3160	2.2	3
614	Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015 , 126, 3202-3202 ¹	2.2	1
613	Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study. <i>Blood</i> , 2015 , 126, 3246-3246	2.2	10

612	Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients. <i>Blood</i> , 2015 , 126, 351-351	2.2	1
611	Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients. <i>Blood</i> , 2015 , 126, 3989-3989	2.2	3
610	Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , 2015 , 126, 4073-4073	2.2	2
609	Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs. <i>Blood</i> , 2015 , 126, 4080-4080	2.2	3
608	Feasibility of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study. <i>Blood</i> , 2015 , 126, 66-66	2.2	2
607	Treatment with Anti-CD19 BiTE \square Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 861-861	2.2	4
606	Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas. <i>PLoS ONE</i> , 2015 , 10, e0121822	3.7	7
605	Use of Lenalidomide in DEL(5q) MDS. a National AIFA (Agenzia Italiana del Farmaco) Registry Study. <i>Blood</i> , 2015 , 126, 1693-1693	2.2	1
604	Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy. <i>Blood</i> , 2015 , 126, 5175-5175	2.2	
603	Platelet Adhesion Under Flow Condition in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV): Analysis According to the Mutational Status. <i>Blood</i> , 2015 , 126, 766-766	2.2	
602	Levels of Minimal Residual Disease Prior to Transplant Influence Outcome of Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 4374-4374	2.2	
601	Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients. <i>Blood</i> , 2015 , 126, 2122-2122	2.2	
600	Impact of Comorbidity Burden in Treatment and Outcome of Older Patients with Indolent Non-Hodgkin Lymphomas. <i>Blood</i> , 2015 , 126, 4503-4503	2.2	
599	Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia. <i>Blood</i> , 2015 , 126, 4055-4055	2.2	
598	Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. <i>American Journal of Hematology</i> , 2014 , 89, 588-90	7.1	58
597	Masked polycythemia vera (mPV): results of an international study. <i>American Journal of Hematology</i> , 2014 , 89, 52-4	7.1	103
596	Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 375-81	4.7	159
595	Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. <i>Bone Marrow Transplantation</i> , 2014 , 49, 485-91	4.4	10

594	A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy. <i>Journal of Immunology</i> , 2014 , 193, 4739-47	5.3	16
593	Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. <i>Leukemia</i> , 2014 , 28, 1885-91	10.7	66
592	A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2014 , 25, 2398-2404	10.3	10
591	Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1080-8	4.7	47
590	Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 872-80	4.7	111
589	Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 885-90	4.7	37
588	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. <i>Leukemia Research</i> , 2014 , 38, 155-60	2.7	24
587	Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>Hematologica</i> , 2014 , 99, 916-21	6.6	49
586	Role of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014 , 6, e2014065 ³⁻²		5
585	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2014 , 124, 1183-91	2.2	111
584	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. <i>Blood</i> , 2014 , 124, 2507-13; quiz 2615	2.2	424
583	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. <i>Blood</i> , 2014 , 123, 3803-10	2.2	65
582	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , 2014 , 123, 2333-42	2.2	119
581	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. <i>Blood</i> , 2014 , 124, e21-32	2.2	89
580	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. <i>Blood</i> , 2014 , 124, 3021-3	2.2	80
579	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. <i>Blood</i> , 2014 , 124, 2611-2	2.2	66
578	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. <i>Transfusion</i> , 2014 , 54, 331-9	2.9	19
577	Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014 , 6, e2014062	3.2	8

576	Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. <i>Haematologica</i> , 2014 , 99, e94-7	6.6	21
575	Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2014 , 4, e225	7	49
574	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. <i>Leukemia</i> , 2014 , 28, 779-86	10.7	81
573	Prognostic impact of minimal residual disease in adult acute lymphoblastic leukemia. <i>International Journal of Hematologic Oncology</i> , 2014 , 3, 419-431	1	
572	Highly aggressive T-cell acute lymphoblastic leukemia with t(8;14)(q24;q11): extensive genetic characterization and achievement of early molecular remission and long-term survival in an adult patient. <i>Blood Cancer Journal</i> , 2014 , 4, e176	7	6
571	Quality of harvest and role of cell dose in unrelated bone marrow transplantation: an Italian Bone Marrow Donor Registry-Gruppo Italiano Trapianto di Midollo Osseo Study. <i>Hematology</i> , 2014 , 19, 1-9	2.2	6
570	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. <i>Cancer</i> , 2014 , 120, 513-20	6.4	139
569	Masked polycythemia vera diagnosed according to WHO and BCSH classification. <i>American Journal of Hematology</i> , 2014 , 89, 199-202	7.1	51
568	Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study. <i>American Journal of Hematology</i> , 2014 , 89, E200-5	7.1	38
567	Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. <i>American Journal of Hematology</i> , 2014 , 89, 68-73	7.1	42
566	Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells. <i>Experimental Hematology</i> , 2014 , 42, 1013-21.e1	3.1	20
565	Myeloblastic therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up. <i>British Journal of Haematology</i> , 2014 , 167, 724-6	4.5	4
564	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. <i>British Journal of Haematology</i> , 2014 , 167, 541-6	4.5	29
563	Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. <i>Cytotherapy</i> , 2014 , 16, 101-10	4.8	5
562	Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18-year follow-up of 488 patients (IELSG 23 study). <i>Annals of Hematology</i> , 2014 , 93, 221-231	3	27
561	Experts' considerations on HLA-haploidentical stem cell transplantation. <i>European Journal of Haematology</i> , 2014 , 93, 187-97	3.8	23
560	Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. <i>Blood</i> , 2014 , 124, 150-150	2.2	2
559	Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. <i>Blood</i> , 2014 , 124, 1824-1824	2.2	1

558	Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea. <i>Blood</i> , 2014 , 124, 1847-1847	2.2	11
557	Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients. <i>Blood</i> , 2014 , 124, 1848-1848	2.2	2
556	Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study). <i>Blood</i> , 2014 , 124, 1849-1849 ^{2.2}	2.2	2
555	Rare Igh Translocations in Newly Diagnosed Multiple Myeloma (MM) Patients: Cytogenetic Characterization and Relevance on Prognosis. <i>Blood</i> , 2014 , 124, 2042-2042	2.2	1
554	Role of Allogeneic Stem Cell Transplantation (AlloSCT) in Patients Affected By Peripheral T-Cell Lymphomas (PTCL): No Difference in Outcome Between Patients Allografted at Diagnosis and in First Chemosensitive Relapse. <i>Blood</i> , 2014 , 124, 2574-2574	2.2	1
553	A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group. <i>Blood</i> , 2014 , 124, 3192-3192	2.2	1
552	Chronic Graft-Versus-Host Disease after Allogeneic Stem Cell Transplant with in Vivo T-Cell Depletion By Alemtuzumab: Incidence, Outcome and Pattern of Organ Involvement. <i>Blood</i> , 2014 , 124, 3912-3912	2.2	1
551	Allogeneic HCT with Reduced Intensity Conditioning Versus Autologous HCT for >55 Years Old Patients with Acute Lymphoblastic Leukemia in First Complete Remission: An Analysis from Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2014 , 124, 3974-3974	2.2	2
550	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. <i>Blood</i> , 2014 , 124, 405-405	2.2	39
549	Acute Myeloid Leukemia Relapses after Allogeneic HSCT Display a Distinctive Immune-Related Signature, with Frequent and Functionally Relevant Alterations in HLA Class II Antigen Presentation and T Cell Costimulation. <i>Blood</i> , 2014 , 124, 427-427	2.2	9
548	Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Revised International Prognostic Scoring System (IPSS-R). <i>Blood</i> , 2014 , 124, 531-531	2.2	2
547	Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2014 , 124, 507-507	2.2	1
546	Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014 , 124, 965-965	2.2	4
545	Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival. <i>PLoS ONE</i> , 2014 , 9, e106745	3.7	16
544	Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia. <i>Oncoscience</i> , 2014 , 1, 510-21	0.8	28
543	Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. <i>Oncotarget</i> , 2014 , 5, 4665-70	3.3	24
542	Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML. <i>Blood</i> , 2014 , 124, 1794-1794	2.2	1
541	Safety and Efficacy of Thiotepe-Based Conditioning Therapy for Allogeneic Transplantation in Acute Myeloid Leukemia - a Survey from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2014 , 124, 3895-3895	2.2	

540	Factors Predicting Outcome after Allogeneic Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia: A Retrospective Analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2014 , 124, 731-731	2.2	
539	Contrasting Factors Determine the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a Survey from the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2014 , 124, 3945-3945	2.2	
538	Next Generation Sequencing (NGS) of TP53 Gene Allows to Identify a Very High Risk Group of Philadelphia Negative Acute Lymphoblastic Leukemia (ALL) Patients. <i>Blood</i> , 2014 , 124, 3796-3796	2.2	
537	Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study. <i>Blood</i> , 2014 , 124, 421-421	2.2	
536	Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group. <i>Blood</i> , 2014 , 124, 3179-3179	2.2	
535	Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia. <i>Blood</i> , 2014 , 124, 404-404	2.2	
534	Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study. <i>Blood</i> , 2014 , 124, 1867-1867	2.2	
533	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014 , 124, 1230-1230	2.2	0
532	ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. <i>Thrombosis Research</i> , 2013 , 132, 88-93	8.2	27
531	Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. <i>New England Journal of Medicine</i> , 2013 , 369, 111-21	59.2	964
530	A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. <i>British Journal of Haematology</i> , 2013 , 161, 688-94	4.5	91
529	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013 , 88, 581-8	7.1	46
528	Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms. <i>Immunology Letters</i> , 2013 , 155, 27-30	4.1	29
527	Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue. <i>Expert Review of Hematology</i> , 2013 , 6, 429-39	2.8	8
526	Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. <i>Experimental Hematology</i> , 2013 , 41, 627-34	3.1	16
525	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013 , 54, 62-8	1.9	13
524	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. <i>Transplant International</i> , 2013 , 26, 867-78	3	129
523	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. <i>MABs</i> , 2013 , 5, 826-37	6.6	83

522	Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. <i>Leukemia</i> , 2013 , 27, 2084-6	10.7	39
521	SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. <i>American Journal of Hematology</i> , 2013 , 88, 185-92	7.1	28
520	Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1387-92	4.7	20
519	The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Societ�Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey. <i>Transfusion and Apheresis Science</i> , 2013 , 49, 615-22	2.4	7
518	Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. <i>Experimental Hematology</i> , 2013 , 41, 253-60.e2	3.1	23
517	Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 940-8	4.7	17
516	The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2013 , 48, 1409-14	4.4	52
515	Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2761-2	2.2	29
514	The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. <i>American Journal of Hematology</i> , 2013 , 88, 1062-7	7.1	44
513	Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. <i>Journal of Immunology</i> , 2013 , 190, 231-9	5.3	85
512	Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. <i>Leukemia</i> , 2013 , 27, 1511-9	10.7	94
511	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Leukemia</i> , 2013 , 27, 2086-91	10.7	31
510	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. <i>Leukemia</i> , 2013 , 27, 1874-81	10.7	389
509	Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. <i>Blood</i> , 2013 , 121, 2529-32	2.2	51
508	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. <i>Blood</i> , 2013 , 122, 3482-91	2.2	172
507	High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. <i>Haematologica</i> , 2013 , 98, 1718-25	6.6	32
506	The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. <i>PLoS ONE</i> , 2013 , 8, e58424	3.7	21
505	A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results. <i>Blood</i> , 2013 , 122, 1583-1583	2.2	2

504	High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect. <i>Blood</i> , 2013 , 122, 2059-2059 ²		
503	Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients. <i>Blood</i> , 2013 , 122, 3272-3272	2.2	1
502	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. <i>Blood</i> , 2013 , 122, 394-394	2.2	13
501	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. <i>Blood</i> , 2013 , 122, 4067-4067	2.2	6
500	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. <i>Blood</i> , 2013 , 122, 4068-4068	2.2	1
499	Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). <i>Blood</i> , 2013 , 122, 4087-4087	2.2	7
498	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). <i>Blood</i> , 2013 , 122, 4088-4088	2.2	6
497	A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2013 , 122, 4177-4177	2.2	2
496	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013 , 122, 770-770	2.2	2
495	NK leukemia: a rare case of oral manifestations representing the initial sign. <i>Annali Di Stomatologia</i> , 2013 , 4, 28		
494	Identification By Gene Expression Profiling Of CIITA-Dependent HLA Class II Transcriptional Downregulation As a Novel Mechanism Of Leukemia Immune Escape and Relapse After Allogeneic HSCT. <i>Blood</i> , 2013 , 122, 3748-3748	2.2	
493	Increased Platelet Thrombus Formation Under Flow Condition In Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2013 , 122, 33-33	2.2	
492	The Long-Term Outcome Of Adult Patients With Acute Myeloid Leukemia NPM+ and FLT3/ITD- Is Not Significantly Improved By The Application Of An Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2013 , 122, 2648-2648	2.2	
491	Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis. <i>Blood</i> , 2013 , 122, 1600-1600	2.2	
490	Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCytel) In Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013 , 122, 3901-3901	2.2	
489	Quantitative DNA Real-Time PCR Compared To mRNA and Cytogenetic Assays To Monitor Minimal Residual Disease In Chronic Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 1316-1316	2.2	
488	Nilotinib For Steroid-Refractory Chronic Graft Versus Host Disease (SR-cGVHD): Preliminary Results Of a Phase I-II GITMO Study (Gruppo Italiano Trapianto di Midollo Osseo). <i>Blood</i> , 2013 , 122, 4608-4608	2.2	
487	Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients A Report From The Acute Leukemia Working Party Of EBMT. <i>Blood</i> , 2013 , 122, 921-921	2.2	

486	The Revised International Prognostic Scoring System (IPSS-R) Predicts Posttransplantation Outcome Of Patients With Myelodysplastic Syndrome Receiving Allogeneic Stem Cell Transplantation: A Basis For Clinical Decision Making. <i>Blood</i> , 2013 , 122, 2765-2765	2.2	
485	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. <i>American Journal of Hematology</i> , 2012 , 87, 203-4	7.1	22
484	Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2012 , 91, 73-82	3	25
483	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. <i>Blood</i> , 2012 , 119, 2239-41	2.2	73
482	Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. <i>Blood</i> , 2012 , 120, 1327-33	2.2	72
481	The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. <i>Experimental Hematology</i> , 2012 , 40, 634-45.e10	3.1	30
480	Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. <i>Bone Marrow Transplantation</i> , 2012 , 47, 1474-8	4.4	29
479	High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 788-93	4.7	77
478	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, S216	4.7	4
477	Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). <i>Blood</i> , 2012 , 120, 5128-33; quiz 5252	2.2	340
476	Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. <i>Blood</i> , 2012 , 120, 569-71	2.2	60
475	Rituximab in idiopathic membranous nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 1416-25	12.7	187
474	p38MAPK interacts with and inhibits RAR β suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells. <i>Leukemia</i> , 2012 , 26, 1850-61	10.7	23
473	Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. <i>Leukemia</i> , 2012 , 26, 716-9	10.7	112
472	Hydroxyurea-related toxicity in 3,411 patients with Ph ⁻ -negative MPN. <i>American Journal of Hematology</i> , 2012 , 87, 552-4	7.1	82
471	Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. <i>Leukemia</i> , 2012 , 26, 1681-4	10.7	56
470	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. <i>Annals of Hematology</i> , 2012 , 91, 931-9	3	56
469	ASXL1 mutations in primary and secondary myelofibrosis. <i>British Journal of Haematology</i> , 2012 , 156, 404-7	4.5	15

468	Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation. <i>Stem Cells International</i> , 2012 , 2012, 690236 ⁵		25
467	A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. <i>Journal of Experimental Medicine</i> , 2012 , 209, 35-50	16.6	60
466	Experience with pegylated interferon α in advanced myeloproliferative neoplasms in an international cohort of 118 patients. <i>Haematologica</i> , 2012 , 97, 1570-3	6.6	69
465	Modern therapy of young and adult Ph-ALL. <i>Leukemia Supplements</i> , 2012 , 1, S5-6	75	2
464	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , 2012 , 26, 1779-85	10.7	13
463	Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. <i>Leukemia</i> , 2012 , 26, 520-6	10.7	101
462	Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. <i>Bone Marrow Transplantation</i> , 2012 , 47, 342-51	4.4	118
461	A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms. <i>Haematologica</i> , 2012 , 97, 1394-400	6.6	19
460	Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4098-103	2.2	252
459	CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. <i>Haematologica</i> , 2012 , 97, 568-71	6.6	21
458	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. <i>Blood</i> , 2012 , 120, 1731-1731	2.2	1
457	Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial. <i>Blood</i> , 2012 , 120, 1984-1984	2.2	1
456	Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses [First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial. <i>Blood</i> , 2012 , 120, 550-550	2.2	2
455	ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AML5G. <i>Blood</i> , 2012 , 120, 120-120	2.2	12
454	Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL). <i>Blood</i> , 2012 , 120, 746-746	2.2	2
453	Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera. <i>Blood</i> , 2012 , 120, 804-804	2.2	3
452	High Cure Rates in Burkitt Leukemia and Lymphoma: NILG Study of the German Short Intensive Rituximab-Chemotherapy Program. <i>Blood</i> , 2012 , 120, 1494-1494	2.2	
451	In Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Imatinib (IM) and Chemotherapy in Combination Improve Remission Rate, Stem Cell Transplantation Rate and Long-Term Outcome. <i>Blood</i> , 2012 , 120, 662-662	2.2	

450	Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia Compared with the General Population. <i>Blood</i> , 2012 , 120, 2056-2056	2.2	
449	Early Response Dynamics Including Minimal Residual Disease (MRD) and Adherence to Risk/MRD-Oriented Therapy Are Major Outcome Determinants in Adult Ph-Negative Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2012 , 120, 2573-2573	2.2	
448	Lenalidomide in Myelodysplastic Syndromes with 5q Deletion. Results From the Italian National Cancer Registry. <i>Blood</i> , 2012 , 120, 3850-3850	2.2	
447	In Vivo T Cell Depletion with Antithymocyte Globulin or Alemtuzumab for Unrelated Donor Stem Cell Transplantation with Reduced Intensity Conditioning: Results of a Multicenter Randomized Phase II Clinical Trial (The Global Study) From the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2012 , 120, 331-331	2.2	
446	Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL): Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2012 , 120, 3105-3105	2.2	
445	Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients. <i>Blood</i> , 2012 , 120, 743-743	2.2	1
444	Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2012 , 120, 1975-1975	2.2	
443	Primary Refractory Disease in Non-Hodgkin's Lymphoma: A Retrospective Study On 3,952 Newly Diagnosed Patients Undergoing First-Line Chemotherapy. <i>Blood</i> , 2012 , 120, 305-305	2.2	
442	Role of Front-Line High Dose Therapy with Stem Cell Transplant in Peripheral T-Cell Lymphomas. A Single Center Experience.. <i>Blood</i> , 2012 , 120, 2733-2733	2.2	
441	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. <i>Blood</i> , 2012 , 120, 1726-1726	2.2	
440	The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab. <i>Blood</i> , 2012 , 120, 1553-1553	2.2	
439	Validation of the Cibmtr Score in Predicting the Outcome of Hematopoietic Stem-Cell Transplantation in AML Patients Not in Complete Remission At the Time of Conditioning: A Retrospective Analysis On Behalf of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2012 , 120, 2005-2005	2.2	
438	Ultra Rapid, One Step Molecular Detection of BCR-ABL Major and Minor Transcripts by Isothermal RT-Loop Mediated Amplification Reaction.. <i>Blood</i> , 2012 , 120, 2515-2515	2.2	
437	In Adult Acute Lymphoblastic Leukemia (ALL) Different Minimal Residual Disease (MRD) Levels Predict Clinical Outcome in All Patients and Response to Allogeneic/Autologous Transplantation in MRD-Positive Patients.. <i>Blood</i> , 2012 , 120, 2493-2493	2.2	0
436	Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy. <i>Blood</i> , 2012 , 120, 4234-4234	2.2	
435	Long Telomere Length of White Blood Cells Following Umbilical Cord Blood Transplant (UCBT): Is Hematopoiesis Younger in UCBT Recipients Compared to Healthy Age-Matched Controls?. <i>Blood</i> , 2012 , 120, 4094-4094	2.2	
434	Comparison of the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. <i>Blood</i> , 2012 , 120, 2852-2852	2.2	
433	Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?.. <i>Blood</i> , 2012 , 120, 3083-3083	2.2	

432	Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.. <i>Blood</i> , 2012 , 120, 2849-2849	2.2	
431	Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. <i>Cytotherapy</i> , 2011 , 13, 786-801	4.8	93
430	Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 412-22	6.9	231
429	Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. <i>Blood</i> , 2011 , 118, 4554-60	2.2	175
428	Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. <i>Blood</i> , 2011 , 118, 3301-10	2.2	153
427	JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. <i>Blood</i> , 2011 , 118, 2599-601	2.2	54
426	Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. <i>Blood</i> , 2011 , 117, 510-8	2.2	49
425	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. <i>Blood</i> , 2011 , 117, 4716-25	2.2	147
424	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. <i>Blood</i> , 2011 , 118, 401-8	2.2	215
423	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. <i>Blood</i> , 2011 , 118, 2069-76	2.2	126
422	Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2011 , 152, 777-80	4.5	14
421	Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. <i>British Journal of Haematology</i> , 2011 , 152, 551-60	4.5	115
420	Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011 , 118, 6153-63	2.2	191
419	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011 , 90, 401-8	3	21
418	Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD). <i>Pediatric Blood and Cancer</i> , 2011 , 57, 324-8	3	7
417	Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. <i>American Journal of Hematology</i> , 2011 , 86, 337-42	7.1	57
416	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , 2011 , 52, 823-32	1.9	20
415	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. <i>Haematologica</i> , 2011 , 96, 315-8	6.6	126

414	ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. <i>New England Journal of Medicine</i> , 2011 , 365, 203-12	59.2	282
413	Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. <i>Journal of Immunology</i> , 2011 , 186, 3762-9	5.3	156
412	A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2140-5	5.1	25
411	Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 814-24	2.2	122
410	Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study. <i>Blood</i> , 2011 , 118, 1647-1647	2.2	6
409	A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy. <i>Blood</i> , 2011 , 118, 1748-1748	2.2	6
408	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. <i>Blood</i> , 2011 , 118, 1750-1750	2.2	1
407	Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry. <i>Blood</i> , 2011 , 118, 2009-2009	2.2	1
406	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. <i>Blood</i> , 2011 , 118, 277-277	2.2	4
405	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. <i>Blood</i> , 2011 , 118, 3839-3839	2.2	4
404	A Phase II Study of Sequential Administration of DLI and Cytokine Induced Killer (CIK) Cells in Patients with Hematologic Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation: Preliminary Results. <i>Blood</i> , 2011 , 118, 657-657	2.2	1
403	Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 6610-6610	2.2	4
402	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1) At the Era of Tyrosine Kinase Inhibitors (TKI): A Survey From the Acute Leukemia Working Party (ALWP) of EBMT. <i>Blood</i> , 2011 , 118, 4107-4107	2.2	
401	Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATCL): A Retrospective Study of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2011 , 118, 3115-3115	2.2	
400	Activated FVII-Antithrombin Complex and Tissue Factor mRNA As Potential Markers of Severe Thrombo-Hemorrhagic Syndrome in APL Patients. <i>Blood</i> , 2011 , 118, 1195-1195	2.2	
399	Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasms (MPN): International Experience in 115 Cases. <i>Blood</i> , 2011 , 118, 2818-2818	2.2	
398	Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. <i>Blood</i> , 2011 , 118, 1682-1682	2.2	1682
397	Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Who Classification-Based Prognostic Scoring System (WPSS). <i>Blood</i> , 2011 , 118, 116-116	2.2	

396	The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party. <i>Blood</i> , 2011 , 118, 502-502	2.2	
395	Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm. <i>Blood</i> , 2011 , 118, 5148-5148	2.2	
394	Chronic Myeloid Leukemia: Molecular Monitoring of Residual Disease by Genomic DNA Compared to Conventional mRNA Analysis in Follow-Ups up to 8 Years. <i>Blood</i> , 2011 , 118, 1687-1687	2.2	
393	A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM). <i>Blood</i> , 2011 , 118, 805-805	2.2	
392	Whole-Exome Sequencing Identifies Recurrent Mutations of BCOR in Acute Myeloid Leukemia with Normal Karyotype. <i>Blood</i> , 2011 , 118, 71-71	2.2	1
391	Unrelated Cord Blood Transplantation Using Myeloablative Conditioning Regimen for Adults with Acute Myeloid Leukemia in First Complete Remission. A Survey by EUROCORD and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2011 , 118, 836-836	2.2	
390	Genomic and Transcriptional Immunoediting of Acute Myeloid Leukemia in Response to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2011 , 118, 329-329	2.2	
389	Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 149, 569-77	4.5	45
388	A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2010 , 150, 446-55	4.5	174
387	Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. <i>Leukemia</i> , 2010 , 24, 521-35	10.7	246
386	Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3644-52	2.2	209
385	Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Haematologica</i> , 2010 , 95, 983-8	6.6	43
384	Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1293-301	4.7	149
383	Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1603-7	4.7	46
382	Thrombosis in primary myelofibrosis: incidence and risk factors. <i>Blood</i> , 2010 , 115, 778-82	2.2	175
381	Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. <i>Haematologica</i> , 2010 , 95, 260-9	6.6	34
380	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. <i>Haematologica</i> , 2010 , 95, 476-84	6.6	116
379	Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. <i>Blood</i> , 2010 , 116, 1051-5	2.2	46

378	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010 , 116, 3171-9	2.2	249
377	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. <i>Haematologica</i> , 2010 , 95, 1435-8	6.6	37
376	A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. <i>Annals of Hematology</i> , 2010 , 89, 185-90	3	94
375	Therapy of myelofibrosis (excluding JAK2 inhibitors). <i>International Journal of Hematology</i> , 2010 , 91, 180-83	8.3	5
374	Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. <i>Experimental Hematology</i> , 2010 , 38, 259-269.e2	3.1	8
373	Understanding the Immunomodulatory Effect of Mesenchymal Stem Cell Infused In Transplanted Patients with Steroid-Refractory GvHD. <i>Blood</i> , 2010 , 116, 2306-2306	2.2	2
372	Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). <i>Blood</i> , 2010 , 116, 313-313	2.2	22
371	A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results. <i>Blood</i> , 2010 , 116, 314-314	2.2	5
370	Improved Clinical Outcome of Adult Patients with Ph+ ALL After a Combined Imatinib-Chemotherapy Induction/Consolidation Program Followed by Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Prospective Study of the Northern Italy Leukemia Group. <i>Blood</i> , 2010 , 116, 682-682	2.2	1
369	Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients. <i>Blood</i> , 2010 , 116, 5060-5060	2.2	
368	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients. <i>Blood</i> , 2010 , 116, 4095-4095	2.2	
367	Telomere Length In Ph - Negative Chronic Myeloproliferative Neoplasms: It Is Reduced According to JAK2 V617F Mutation Allele Burden and It Is Not Affected by Cytoreductive Treatment with Hydroxyurea. <i>Blood</i> , 2010 , 116, 1975-1975	2.2	
366	ADP-Induced Whole Blood Aggregometry and Platelet-Associated Thrombin Generation (TG) In Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Patients. <i>Blood</i> , 2010 , 116, 1981-1981	2.2	
365	Interim-PET Scan Interpretation In the Ongoing Prospective Clinical Trial HD 0607, In Advanced-Stage Hodgkin Lymphoma: Results of the the Expert Panel Review. <i>Blood</i> , 2010 , 116, 3891-3891	2.2	
364	Pediatric-Type Therapy Including Lineage-Targeted Methotrexate to Improve Early Minimal Residual Disease Response and Survival In Adult Acute Lymphoblastic Leukemia (ALL): Interim Analysis of Northern Italy Leukemia Group Study 10/07. <i>Blood</i> , 2010 , 116, 2131-2131	2.2	
363	The HDAC INHIBITOR ITF2357 MODULATES KEY HEMATOPOIETIC GENES in JAK2V617F CELLS From MYELOPROLIFERATIVE Neoplasm PATIENTS. <i>Blood</i> , 2010 , 116, 797-797	2.2	
362	Enhanced Killing of Human B Lymphoma Targets by Combined Use of Cytokine Induced Killer (CIK) Cultures and Anti-CD20 Antibodies. <i>Blood</i> , 2010 , 116, 4285-4285	2.2	
361	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥5 years) Ph+ CML Patients [EudraCT Number 2007005102-42, ClinicalTrials.gov NCT 00858806.. <i>Blood</i> , 2010 , 116, 3412-3412	2.2	

360	Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients. <i>Blood</i> , 2010 , 116, 2273-2273	2.2	
359	Microparticle-Associated Thrombin Generation and Procoagulant Activity Is Increased In Patients with Essential Thrombocythemia. <i>Blood</i> , 2010 , 116, 1985-1985	2.2	
358	Inhibition of the peptidyl-prolyl-isomerase Pin1 enhances the responses of acute myeloid leukemia cells to retinoic acid via stabilization of RARalpha and PML-RARalpha. <i>Cancer Research</i> , 2009 , 69, 1016-26 ^{10.1}	52	
357	Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Clinical Infectious Diseases</i> , 2009 , 49, 1226-36	11.6	44
356	Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 1437-50	5.6	18
355	JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. <i>Experimental Hematology</i> , 2009 , 37, 1016-21	3.1	78
354	A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. <i>British Journal of Haematology</i> , 2009 , 147, 681-5	4.5	7
353	High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. <i>Bone Marrow Transplantation</i> , 2009 , 43, 509-11	4.4	25
352	HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. <i>Bone Marrow Transplantation</i> , 2009 , 44, 571-7	4.4	39
351	Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). <i>Blood</i> , 2009 , 113, 4153-62	2.2	323
350	The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. <i>Cytotherapy</i> , 2009 , 11, 403-13	4.8	22
349	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. <i>Blood</i> , 2009 , 114, 1477-83	2.2	168
348	Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis. <i>Journal of Molecular Diagnostics</i> , 2009 , 11, 482-7	5.1	23
347	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood</i> , 2009 , 113, 3375-82	2.2	81
346	Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. <i>Blood</i> , 2009 , 114, 759-63	2.2	118
345	Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. <i>Transplantation</i> , 2009 , 88, 614-9	1.8	58
344	Hematopoietic Progenitor Cells From Patients with Chronic Mountain Sickness Lack the JAK2V617F Mutation, Show Hypersensitivity to Erythropoietin and Are Inhibited by Statins.. <i>Blood</i> , 2009 , 114, 1894-1894	2.2	2
343	Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors.. <i>Blood</i> , 2009 , 114, 2915-2915	2.2	1

342	RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF).. <i>Blood</i> , 2009 , 114, 307-307	2.2	8
341	A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.. <i>Blood</i> , 2009 , 114, 311-311	2.2	24
340	Predominant Complement Mediated Lysis of B-CLL Cells by Therapeutic MABs Rituximab and Campath-1H in Whole Blood Assays.. <i>Blood</i> , 2009 , 114, 3445-3445	2.2	1
339	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , 2009 , 114, 860-860	2.2	1
338	A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease?.. <i>Blood</i> , 2009 , 114, 882-882	2.2	1
337	Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up.. <i>Blood</i> , 2009 , 114, 875-875	2.2	
336	Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.. <i>Blood</i> , 2009 , 114, 2199-2199	2.2	
335	High-Sensitivity C-Reactive Protein (hs-CRP) and Pentraxin 3 (PTX3) Are Increased in Essential Thrombocythemia and Polycythemia Vera.. <i>Blood</i> , 2009 , 114, 1911-1911	2.2	
334	Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An-ALWP-EBMT Survey.. <i>Blood</i> , 2009 , 114, 195-195	2.2	
333	Short Chemotherapy-Phased Imatinib (IM) Pulses Improve Long-Term Outcome of Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL).. <i>Blood</i> , 2009 , 114, 2029-2029	2.2	
332	Changes of JAK2 V617F Allele Burden Over Time in Patients with Polycythemia Vera or Essential Thrombocythemia: A Retrospective Study of 172 Patients.. <i>Blood</i> , 2009 , 114, 1892-1892	2.2	
331	High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.. <i>Blood</i> , 2009 , 114, 519-519	2.2	
330	Male Gender, Quality of Grafted Cells, Advanced Age, Rituximab and Radiotherapy Are the Main Factors That Variously Influence the Occurrence of Secondary Malignancies Following High-Dose Therapy and Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in 1,347 Lymphoma Patients.. <i>Blood</i> , 2009 , 114, 519-519	2.2	
329	Correlation of Novel Molecular Markers in Patients with Myeloproliferative Neoplasms.. <i>Blood</i> , 2009 , 114, 4968-4968	2.2	
328	Cytokine Induced Killer Cells Can Kill Target through Antigen/TCR Dependent and Independent Mechanisms: New Clinical Perspectives of Utilisation.. <i>Blood</i> , 2009 , 114, 3024-3024	2.2	
327	Caspofungin Primary Antifungal Prophylaxis in Acute Leukemia Patients During Induction Therapy: Results of a Prospective Phase II Multicentric Study (ProfilC Study).. <i>Blood</i> , 2009 , 114, 1638-1638	2.2	
326	A Novel, Highly Sensitive, Rapid, Non-PCR Based Method for the Detection of the JAK2 V617F Mutation in Chronic Myeloproliferative Neoplasms.. <i>Blood</i> , 2009 , 114, 3892-3892	2.2	
325	The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). <i>Leukemia</i> , 2008 , 22, 740-7	10.7	120

324	Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 1167-78	6.1	143
323	Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innovative nei linfomi survey. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3166-75	2.2	58
322	Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2008 , 93, 303-6	6.6	91
321	Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. <i>Aids</i> , 2008 , 22, 1236-7	3.5	27
320	From palliation to epigenetic therapy in myelofibrosis. <i>Hematology American Society of Hematology Education Program</i> , 2008 , 83-91	3.1	9
319	Leukocytosis and risk stratification assessment in essential thrombocythemia. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2732-6	2.2	150
318	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. <i>Blood</i> , 2008 , 112, 844-7	2.2	198
317	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Blood</i> , 2008 , 112, 895-902	2.2	165
316	Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008 , 111, 4004-13	2.2	200
315	Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. <i>Blood</i> , 2008 , 112, 3135-7	2.2	94
314	Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. <i>Haematologica</i> , 2008 , 93, 1837-42	6.6	79
313	Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2008 , 47, 625-32	5	41
312	Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. <i>American Journal of Hematology</i> , 2008 , 83, 717-20	7.1	18
311	Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. <i>Stem Cells</i> , 2008 , 26, 2075-82	5.8	326
310	A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2V617F Positive Chronic Myeloproliferative Neoplasms. <i>Blood</i> , 2008 , 112, 100-100	2.2	21
309	Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients.. <i>Blood</i> , 2008 , 112, 1099-1099	2.2	1
308	High Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using Patients as Their Own Controls.. <i>Blood</i> , 2008 , 112, 2191-2191	2.2	1
307	Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2008 , 112, 2202-2202	2.2	1

306	Outcome of Adult AML at First Relapse Following a Risk-Oriented Strategy: An Update of the Northern Italy Leukemia Group (NILG) Experience. <i>Blood</i> , 2008 , 112, 4385-4385	2.2	1
305	Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups. <i>Journal of Clinical Oncology</i> , 2008 , 26, 8506-8506	2.2	16
304	BEACOPP Chemotherapy Is Able to Induce Durable Complete Remission in Poor-Prognosis Hodgkin Lymphoma Patients with a Positive Interim PET after 2 ABVD Cycles. <i>Blood</i> , 2008 , 112, 2594-2594	2.2	16
303	The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study). <i>Blood</i> , 2008 , 112, 3608-3608	2.2	
302	Impact of V617F JAK2 Mutation on Monocyte Tissue Factor and Procoagulant Activity in Patients with Essential Thrombocythemia(ET) or Polycythemia VERA (PV). <i>Blood</i> , 2008 , 112, 3736-3736	2.2	
301	Clinical Relevance of JAK2V617F Allele Burden in Primary and Post-Polycythemic/Post-Thrombocythemic Myelofibrosis. <i>Blood</i> , 2008 , 112, 2799-2799	2.2	
300	Human Mesenchymal Stroma Cells (hMSCs) Expanded with Human Platelets Lysate Are Safe and Effective For the Treatment of Graft Versus Host Disease. <i>Blood</i> , 2008 , 112, 1171-1171	2.2	1
299	Similar Rate of Thrombosis in Essential Thrombocythemia and Polycythemia Vera Patients after Stratification for JAK2 V617F Allele Burden.. <i>Blood</i> , 2008 , 112, 1745-1745	2.2	
298	FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. <i>Haematologica</i> , 2007 , 92, 1127-30	6.6	82
297	Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. <i>American Journal of Hematology</i> , 2007 , 82, 863-6	7.1	17
296	Expansion of B cell precursors after unrelated cord blood transplantation for an adult patient. <i>Bone Marrow Transplantation</i> , 2007 , 40, 283-5	4.4	5
295	Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. <i>Bone Marrow Transplantation</i> , 2007 , 40, 785-91	4.4	133
294	Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. <i>Leukemia</i> , 2007 , 21, 2316-23	10.7	124
293	Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. <i>Leukemia</i> , 2007 , 21, 1952-9	10.7	273
292	The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. <i>Leukemia</i> , 2007 , 21, 1892-900	10.7	94
291	Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy. <i>British Journal of Haematology</i> , 2007 , 137, 216-20	4.5	19
290	Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect?. <i>Therapeutic Apheresis and Dialysis</i> , 2007 , 11, 85-93	1.9	50
289	Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. <i>The Cochrane Library</i> , 2007 , CD003620	2.2	29

288	Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. <i>Haematologica</i> , 2007 , 92, 952-9	6.6	148
287	Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. <i>Haematologica</i> , 2007 , 92, 612-8	6.6	111
286	Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. <i>Blood</i> , 2007 , 109, 2310-3	2.2	255
285	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. <i>Blood</i> , 2007 , 110, 840-6	2.2	368
284	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. <i>Blood</i> , 2007 , 110, 4030-6	2.2	207
283	Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. <i>Haematologica</i> , 2007 , 92, 135-6	6.6	115
282	A Phase II Multiple Dose Clinical Trial of Histone Deacetylase Inhibitor ITF2357 in Patients with Relapsed or Progressive Multiple Myeloma: Preliminary Results.. <i>Blood</i> , 2007 , 110, 1175-1175	2.2	9
281	Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2007 , 110, 1282-1282	2.2	2
280	WHO Classification and WPSS Score Predict Post-Transplant Outcome in Adults with Myelodysplastic Syndrome: A Retrospective Study by GITMO - Gruppo Italiano Trapianto Midollo Osseo.. <i>Blood</i> , 2007 , 110, 1466-1466	2.2	1
279	Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (FL): Updated Results Suggest the Use of R-HDS as Salvage Treatment.. <i>Blood</i> , 2007 , 110, 20-20	2.2	1
278	The Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents with Recurring Hodgkin's Lymphoma: An EBMT Study on 151 Patients.. <i>Blood</i> , 2007 , 110, 3061-3061	2.2	1
277	Selective Targeting of the JAK2V617F Mutation in Polycythemia Vera and Essential Thrombocythemia by ITF2357, a Novel Histone Deacetylase Inhibitor.. <i>Blood</i> , 2007 , 110, 555-555	2.2	3
276	The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation.. <i>Blood</i> , 2007 , 110, 678-678	2.2	3
275	A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo.. <i>Blood</i> , 2007 , 110, 3026-3026	2.2	
274	Efficacy of High-Dose Sequential Chemotherapy and Autograft for Transformed Non Hodgkin's B Cell Lymphoma: Results of a Retrospective Analysis from GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).. <i>Blood</i> , 2007 , 110, 3440-3440	2.2	
273	Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.. <i>Blood</i> , 2007 , 110, 3497-3497	2.2	
272	High-Dose Sequential Chemotherapy (HDS) Followed by Autologous Stem Cell Transplantation (ASCT) in Relapsing/Refractory Hodgkin Lymphoma (HL): Long-Term Results.. <i>Blood</i> , 2007 , 110, 5118-5118	2.2	
271	Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007 , 110, 3432-3432	2.2	

270	A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis.. <i>Blood</i> , 2007 , 110, 3540-3540		2.2
269	Effect of HLA-Matching on Outcome of Hematopoietic Stem Cell Transplantation from Unrelated Donors: A IBMDR-GITMO Study.. <i>Blood</i> , 2007 , 110, 3052-3052		2.2
268	A GITIL Prospective Randomized Multicenter Phase III Study of High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Transplantation (ASCT) of Peripheral Blood Stem Cells Versus CHOP and Rituximab Delivered Every 14 Days (R-CHOP-14) in High-Risk Patients with Diffuse Large B-Cell Lymphomas (DLBCL): Interim Analysis on Feasibility and Toxicity (Protocol Autologous Stem Cell Transplantation (ASCT) for Elderly Patients (≥60 Years) with Non-Hodgkin		2.2
267	Lymphoma (NHL): An Analysis Based on EBMT Registry.. <i>Blood</i> , 2007 , 110, 1888-1888		2.2
266	The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following Intensive Therapy and Autograft Correlates with the Type of Cells Grafted: A Survey on 1,347 Lymphoma Patients Receiving the High-Dose Sequential (HDS) Program.. <i>Blood</i> , 2007 , 110, 1083-1083		2.2
265	Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases.. <i>Blood</i> , 2007 , 110, 4465-4465		2.2
264	Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia.. <i>Blood</i> , 2007 , 110, 681-681		2.2
263	Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells. <i>Experimental Hematology</i> , 2006 , 34, 475-85	3.1	10
262	Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders. <i>Hematological Oncology</i> , 2006 , 24, 212-9	1.3	14
261	Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond—the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3959-66	2.2	40
260	S-adenosyl-L-methionine for alcoholic liver diseases. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD002235		50
259	Anabolic-androgenic steroids for alcoholic liver disease. <i>The Cochrane Library</i> , 2006 , CD003045	5.2	14
258	Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2006 , 38, 621-7	4.4	70
257	Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. <i>Leukemia</i> , 2006 , 20, 1533-8	10.7	200
256	Benefit of Rituximab Addition to High-Dose Programs with Autograft for B-Cell Lymphoma: A Multicenter GITIL Survey on 957 Patients.. <i>Blood</i> , 2006 , 108, 207-207	2.2	3
255	Frontline High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Stem Cell Transplantation Induces High Rates of Complete Response and Prolongs Survival in Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2006 , 108, 3045-3045	2.2	2
254	Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS.. <i>Blood</i> , 2006 , 108, 325-325	2.2	2
253	Incidence of Secondary Myelodysplastic Syndrome/Acute Leukemia in 1,266 Lymphoma Patients Following High-Dose Therapy and Autograft: A Study from GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).. <i>Blood</i> , 2006 , 108, 3369-3369	2.2	1

252	Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2006 , 108, 3698-3698	2.2	1
251	Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation Represents a Feasible and Effective Treatment Strategy for Advanced Mycosis Fungoides and Sezary Syndrome.. <i>Blood</i> , 2006 , 108, 2997-2997	2.2	
250	Clinical Significance of JAK2V617F Homozygosity in the Chronic Myeloproliferative Disorders. A Study on 1306 Patients.. <i>Blood</i> , 2006 , 108, 664-664	2.2	
249	Favorable Influence of Rituximab with High Dose Sequential Chemotherapy (R-HDS) Programs and Autologous Stem Cell Transplantation (ASCT) in Salvage Treatment for Patients with Refractory or Relapsed B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , 2006 , 108, 2744-2744	2.2	
248	Potent Inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor.. <i>Blood</i> , 2006 , 108, 2702-2702	2.2	
247	Rapid and Massive Expansion of Cord Blood Derived Cytokine Induced Killer (CIK) Cells: An Innovative Proposal for the Treatment of Leukemia Relapse after Cord Blood Transplantation.. <i>Blood</i> , 2006 , 108, 723-723	2.2	
246	Treosulfan - Fludarabine as Ablative Conditioning Regimen for Patients with High Risk Hematologic Malignancies.. <i>Blood</i> , 2006 , 108, 5248-5248	2.2	
245	Prolonged Survival of Lymphoma Patients Achieving Complete Remission Following High-Dose Sequential Chemotherapy and Autograft (HDS Program): A GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) Retrospective Study on 1,266 Patients.. <i>Blood</i> , 2006 , 108, 3046-3046	2.2	
244	Outcome of Adult AML at First Relapse Following a Risk-Oriented Strategy: The Northern Italy Leukemia Group (NILG) Experience.. <i>Blood</i> , 2006 , 108, 5380-5380	2.2	
243	Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006 , 91, 96-103	6.6	28
242	The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. <i>Haematologica</i> , 2006 , 91, 322-30	6.6	20
241	Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. <i>Cochrane Database of Systematic Reviews</i> , 2005 , CD003620		19
240	Propylthiouracil for alcoholic liver disease. <i>Cochrane Database of Systematic Reviews</i> , 2005 , CD002800		8
239	Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. <i>The Cochrane Library</i> , 2005 , CD002148		30
238	Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. <i>Blood</i> , 2005 , 105, 3428-33	2.2	88
237	Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. <i>Blood</i> , 2005 , 106, 2969-76	2.2	142
236	Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. <i>British Journal of Haematology</i> , 2005 , 128, 310-7	4.5	47
235	Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6690-8	2.2	53

234	Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation (allo-SCT) Is an Effective Salvage Treatment for Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL).. <i>Blood</i> , 2005 , 106, 1128-1128	2.2	2
233	Low Prevalence of JAK2 Val617Phe Mutation in Patients with Idiopathic Erythrocytosis.. <i>Blood</i> , 2005 , 106, 2581-2581	2.2	1
232	Unrelated Hematopoietic Stem Cell Transplantation with Reduced Intensity Regimens in High Risk Patients for Age or Disease: Results from Two Independent Prospective GITMO Studies.. <i>Blood</i> , 2005 , 106, 2888-2888	2.2	1
231	Distinct Hemostatic Profile of Leukocytes in Essential Thrombocythemia (ET) Carrying the JAK2 V617F Mutation.. <i>Blood</i> , 2005 , 106, 378-378	2.2	3
230	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2005 , 106, 659-659	2.2	3
229	Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial.. <i>Blood</i> , 2005 , 106, 675-675	2.2	3
228	Acute Lymphoblastic Leukaemia Cells Carrying the t(12;21) Translocation Are Highly Sensitive to Alemtuzumab Mediated Cell Lysis.. <i>Blood</i> , 2005 , 106, 872-872	2.2	3
227	Bone Marrow BCL2/IgH+ Cells at Diagnosis and Not FCGR3A Polymorphism Predict Response in Follicular Non-Hodgkin's Lymphoma Patients Treated with Sequential CHOP and Rituximab.. <i>Blood</i> , 2005 , 106, 985-985	2.2	1
226	Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2005 , 106, 1836-1836	2.2	
225	Time- and Dose-Response Relationships of Imatinib Mesylate (Gleevec) Therapy for Chronic Hypereosinophilic Syndromes.. <i>Blood</i> , 2005 , 106, 2596-2596	2.2	
224	The Stage-Modified IPI (MIPI), Histology and a Combined Treatment Influence the Clinical Outcome of 401 Patients with Primary Extranodal Head and Neck B-Cell Lymphomas (PHNBCL) (IELSG 23).. <i>Blood</i> , 2005 , 106, 927-927	2.2	
223	JAK2 Val617Phe Mutation Correlates with the Risk of Thrombosis in Patients with Essential Thrombocythemia.. <i>Blood</i> , 2005 , 106, 2580-2580	2.2	4
222	Potent Cytotoxicity Against Multiple Myeloma and Acute Myeloid Leukemia Cells by a New Histone Deacetylase Inhibitor ITF2357.. <i>Blood</i> , 2005 , 106, 3361-3361	2.2	
221	The Addition of Rituximab to High Dose Sequential Chemotherapy (HDS) Programs with Autologous Transplantation Significantly Improves the Outcome of Patients with Refractory or Relapsed B-Cell Non Hodgkin's Lymphoma.. <i>Blood</i> , 2005 , 106, 2084-2084	2.2	
220	Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2005 , 90, 1236-57	6.6	28
219	Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. <i>Haematologica</i> , 2005 , 90, 1643-9	6.6	8
218	Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. <i>Human Gene Therapy</i> , 2004 , 15, 63-76	4.8	81
217	Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2172-6	2.2	252

216	Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways. <i>Journal of Biological Chemistry</i> , 2004 , 279, 42026-40	5-4	33
215	Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency. <i>British Journal of Haematology</i> , 2004 , 124, 604-9	4-5	5
214	Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2004 , 127, 362-4	4-5	21
213	Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia. <i>Leukemia</i> , 2004 , 18, 1441-4	10-7	22
212	Suicide gene therapy and the control of graft-vs-host disease. <i>Best Practice and Research in Clinical Haematology</i> , 2004 , 17, 453-63	4-2	2
211	Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease.. <i>Blood</i> , 2004 , 104, 808-808	2-2	5
210	Long-Term Follow-Up of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Peripheral T-Cell Lymphomas at Diagnosis.. <i>Blood</i> , 2004 , 104, 909-909	2-2	1
209	Treatment of Severe Aplastic Anaemia (SAA) with Antilymphocyte Globulin (ALG), Cyclosporine (CyA) and Granulocyte Colony Stimulating Factor (G-CSF) 5 μ vs 10 μ /Kg : A Gitmo Prospective Randomized Study.. <i>Blood</i> , 2004 , 104, 3700-3700	2-2	
208	Molecular Remission Can Be Attained in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphomas after Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLO-SCT).. <i>Blood</i> , 2004 , 104, 2317-2317	2-2	
207	Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients Older Than 60 Years.. <i>Blood</i> , 2004 , 104, 5134-5134	2-2	
206	A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).. <i>Blood</i> , 2004 , 104, 3261-3261 ²⁻²		
205	Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. <i>Haematologica</i> , 2004 , 89, 1054-61	6-6	19
204	Innovative cell-based therapies in onco-hematology: what are the clinical facts?. <i>Haematologica</i> , 2004 , 89, 1253-60	6-6	8
203	Effect of alemtuzumab on neoplastic B cells. <i>Haematologica</i> , 2004 , 89, 1476-83	6-6	69
202	Anabolic-androgenic steroids for alcoholic liver disease. <i>Cochrane Database of Systematic Reviews</i> , 2003 , CD003045		11
201	Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. <i>Blood</i> , 2003 , 101, 4589-97	2-2	63
200	Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). <i>Blood</i> , 2003 , 102, 749-55	2-2	172
199	Molecular histogenesis of posttransplantation lymphoproliferative disorders. <i>Blood</i> , 2003 , 102, 3775-85	2-2	97

198	Gene expression profile unravels significant differences between childhood and adult Ph+ acute lymphoblastic leukemia. <i>Leukemia</i> , 2003 , 17, 2234-7	10.7	13
197	The course of monoclonal 'villous' lymphocytosis over 15 years of follow-up: progression to SLVL or spontaneous clinical but not molecular remission. <i>Leukemia</i> , 2003 , 17, 2243-4	10.7	1
196	Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. <i>Haematologica</i> , 2003 , 88, 1002-12	6.6	82
195	Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. <i>British Journal of Haematology</i> , 2002 , 116, 202-10	4.5	34
194	Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002 , 118, 1011-8	4.5	12
193	Propylthiouracil for alcoholic liver disease. <i>Cochrane Database of Systematic Reviews</i> , 2002 , CD002800		7
192	Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. <i>Transplantation</i> , 2002 , 74, 1095-102	1.8	119
191	Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. <i>Blood</i> , 2002 , 99, 75-82	2.2	133
190	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. <i>Blood</i> , 2002 , 99, 856-62	2.2	147
189	Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells. <i>Blood</i> , 2002 , 100, 3719-30	2.2	29
188	Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane Review. <i>American Journal of Gastroenterology</i> , 2002 , 97, 1674-1681	0.7	10
187	A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. <i>Human Gene Therapy</i> , 2002 , 13, 1793-807	4.8	52
186	Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups. <i>The Hematology Journal</i> , 2002 , 3, 193-200		9
185	Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia. <i>Haematologica</i> , 2002 , 87, 257-63	6.6	6
184	S-adenosyl-L-methionine for alcoholic liver diseases. <i>Cochrane Database of Systematic Reviews</i> , 2001 , CD002235		16
183	Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha. <i>Blood</i> , 2001 , 97, 3234-43	2.2	59
182	CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. <i>Blood</i> , 2001 , 98, 3383-9	2.2	354
181	Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. <i>Cochrane Database of Systematic Reviews</i> , 2001 , CD002148		15

180	Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001 , 114, 333-41	4.5	30
179	Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. <i>British Journal of Haematology</i> , 2001 , 114, 800-9	4.5	159
178	Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis. <i>Liver</i> , 2001 , 21, 129-36		34
177	Meta-analysis of propylthiouracil for alcoholic liver disease--a Cochrane Hepato-Biliary Group Review. <i>Liver</i> , 2001 , 21, 398-404		33
176	Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions. <i>Leukemia</i> , 2001 , 15, 50-6	10.7	21
175	Prognostic Factors in Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. <i>Hamatologie Und Bluttransfusion</i> , 2001 , 426-431		
174	Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. <i>The Hematology Journal</i> , 2001 , 2, 117-126		28
173	Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. <i>Haematologica</i> , 2001 , 86, 311-5	6.6	6
172	Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. <i>Haematologica</i> , 2001 , 86, 618-23	6.6	25
171	Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. <i>The Hematology Journal</i> , 2001 , 2, 117-26		6
170	Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. <i>Liver</i> , 2000 , 20, 262-6		2
169	Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. <i>Cell Death and Differentiation</i> , 2000 , 7, 447-60	12.7	73
168	Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma. <i>Leukemia</i> , 2000 , 14, 271-7	10.7	53
167	Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure. <i>Hepatology</i> , 2000 , 31, 872-7	11.2	105
166	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , 2000 , 95, 3900-3908	2.2	477
165	Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. <i>Blood</i> , 2000 , 95, 2672-2682	2.2	38
164	Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. <i>Human Gene Therapy</i> , 2000 , 11, 611-20	4.8	108
163	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , 2000 , 95, 3900-3908	2.2	102

162	Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. <i>Blood</i> , 2000 , 95, 2672-2682	2.2	5
161	Possible Prognostic Benefit from ABMT in First Remission Adult Acute Lymphoblastic Leukemia 2000 , 217-225		
160	Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. <i>The Hematology Journal</i> , 2000 , 1, 226-34		14
159	Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. <i>Transplantation</i> , 2000 , 69, 827-33	1.8	126
158	Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. <i>Blood</i> , 2000 , 95, 2672-82	2.2	6
157	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , 2000 , 95, 3900-8	2.2	153
156	Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2000 , 85, 1153-7	6.6	16
155	Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI). <i>Annals of Oncology</i> , 1999 , 10, 427-32	10.3	14
154	The Novel Synthetic Retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene Carboxylic Acid (CD437) Causes Apoptosis in Acute Promyelocytic Leukemia Cells Through Rapid Activation of Caspases. <i>Blood</i> , 1999 , 93, 1045-1061	2.2	75
153	The effects of the level of ampicillin resistance and the inoculum size on the in-vitro bactericidal activity of the combination of ampicillin and ciprofloxacin against high-level gentamicin-resistant strains of <i>Enterococcus faecium</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1999 , 44, 719-20	5.1	
152	Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1999 , 104, 755-62	4.5	15
151	Leucocyte alkaline phosphatase identifies terminally differentiated normal neutrophils and its lack in chronic myelogenous leukaemia is not dependent on p210 tyrosine kinase activity. <i>British Journal of Haematology</i> , 1999 , 105, 163-172	4.5	15
150	Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. <i>Leukemia</i> , 1999 , 13, 664-70	10.7	101
149	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. <i>Leukemia</i> , 1999 , 13, 1901-28	10.7	920
148	Characterization of the human myeloid leukemia-derived cell line GF-D8 by multiplex fluorescence in situ hybridization, subtelomeric probes, and comparative genomic hybridization 1999 , 24, 213-221		25
147	The Novel Synthetic Retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene Carboxylic Acid (CD437) Causes Apoptosis in Acute Promyelocytic Leukemia Cells Through Rapid Activation of Caspases. <i>Blood</i> , 1999 , 93, 1045-1061	2.2	11
146	Clinical sensitivity to anthracyclines in PH/BCR+ acute lymphoblastic leukemia. <i>Advances in Experimental Medicine and Biology</i> , 1999 , 457, 489-99	3.6	4
145	The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. <i>Blood</i> , 1999 , 93, 1045-61	2.2	17

144	Leucocyte alkaline phosphatase identifies terminally differentiated normal neutrophils and its lack in chronic myelogenous leukaemia is not dependent on p210 tyrosine kinase activity. <i>British Journal of Haematology</i> , 1999 , 105, 163-72	4.5	2
143	Characterization of the human myeloid leukemia-derived cell line GF-D8 by multiplex fluorescence in situ hybridization, subtelomeric probes, and comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 1999 , 24, 213-21	5	3
142	Infective endocarditis presenting as polyarthritits. <i>Clinical Rheumatology</i> , 1998 , 17, 518-20	3.9	6
141	Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells. <i>British Journal of Haematology</i> , 1998 , 103, 449-61	4.5	21
140	In-vitro activity of combined ampicillin and ciprofloxacin against high-level gentamicin-resistant strains of <i>Enterococcus faecium</i> : influence of the medium on susceptibility test results. <i>Journal of Antimicrobial Chemotherapy</i> , 1998 , 41, 139-40	5.1	3
139	Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating Factor-Mobilized Circulating Progenitor Cells: Adequacy for Autologous and Allogeneic Transplantation. <i>Blood</i> , 1998 , 91, 2189-2196	2.2	31
138	Flow Cytometry of Leukocyte Alkaline Phosphatase in Human Hematopoietic Cells. <i>Hamatologie Und Bluttransfusion</i> , 1998 , 62-67		
137	Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating Factor-Mobilized Circulating Progenitor Cells: Adequacy for Autologous and Allogeneic Transplantation. <i>Blood</i> , 1998 , 91, 2189-2196	2.2	
136	Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation. <i>Blood</i> , 1998 , 91, 2189-96	2.2	
135	A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia. <i>Haematologica</i> , 1998 , 83, 422-7	6.6	9
134	The role of idarubicin in adult acute lymphoblastic leukaemia: from drug resistance studies to clinical application. <i>Leukemia and Lymphoma</i> , 1997 , 26 Suppl 1, 89-97	1.9	18
133	Combination of co-trimoxazole and ciprofloxacin as therapy of a patient with infective endocarditis caused by an enterococcus highly resistant to gentamicin. <i>Journal of Antimicrobial Chemotherapy</i> , 1997 , 40, 737-8	5.1	8
132	Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs. <i>Leukemia and Lymphoma</i> , 1997 , 26, 153-61	1.9	22
131	Identification of two novel isoforms of the ZNF162 gene: a growing family of signal transduction and activator of RNA proteins. <i>Genomics</i> , 1997 , 42, 268-77	4.3	11
130	Stat1 Is Induced and Activated by All-Trans Retinoic Acid in Acute Promyelocytic Leukemia Cells. <i>Blood</i> , 1997 , 89, 1001-1012	2.2	104
129	A human acute lymphoblastic leukemia line with the T(4;11) translocation as a model of minimal residual disease in SCID mice. <i>Leukemia Research</i> , 1997 , 21, 1107-14	2.7	14
128	BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. <i>British Journal of Haematology</i> , 1997 , 99, 379-85	4.5	23
127	Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1997 , 96, 620-6	4.5	7

126	Flow cytometry of leucocyte alkaline phosphatase in normal and pathologic leucocytes. <i>British Journal of Haematology</i> , 1997 , 96, 815-22	4.5	15
125	Effect of all trans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. <i>International Journal of Cancer</i> , 1997 , 70, 72-7	7.5	19
124	Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. <i>Blood</i> , 1997 , 89, 1001-12	2.2	24
123	Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation Group (GITMO). <i>Haematologica</i> , 1997 , 82, 47-52	6.6	29
122	The natural history of monoclonal villous lymphocytosis: a chronic lymphoproliferative disorder of CD11c+ B cells. <i>Leukemia and Lymphoma</i> , 1996 , 21, 181-3	1.9	3
121	Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 1996 , 21, 457-66	1.9	22
120	Effects of 1,25-dihydroxy vitamin D3 on all-trans retinoic acid sensitive and resistant acute promyelocytic leukemia cells. <i>Biochemical and Biophysical Research Communications</i> , 1996 , 224, 50-6	3.4	20
119	AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. <i>Blood</i> , 1996 , 87, 1520-1531	2.2	64
118	Prevalence of alcohol problems in general practice: an experience from southern Italy. <i>Alcohol and Alcoholism</i> , 1996 , 31, 191-6	3.5	3
117	Detection of the breakpoint cluster region-ABL fusion in chronic myeloid leukemia with variant Philadelphia chromosome translocations by in situ hybridization. <i>Cancer Genetics and Cytogenetics</i> , 1996 , 89, 153-6		5
116	Molecular diagnosis and monitoring of acute myeloid leukemia. <i>Leukemia Research</i> , 1996 , 20, 801-7	2.7	16
115	Interferons induce normal and aberrant retinoic-acid receptors type alpha in acute promyelocytic leukemia cells: potentiation of the induction of retinoid-dependent differentiation markers. <i>International Journal of Cancer</i> , 1996 , 68, 75-83	7.5	17
114	Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia. <i>Acta Haematologica</i> , 1996 , 95, 188-92	2.7	4
113	Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 1996 , 22, 295-301	1.9	37
112	Unorthodox antibiotic combinations including ciprofloxacin against high-level gentamicin resistant enterococci. <i>Journal of Antimicrobial Chemotherapy</i> , 1996 , 37, 727-36	5.1	18
111	The Role of Anthracycline S in the Management of Adult Acute Lymphoblastic Leukaemia 1996 , 215-219		
110	AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. <i>Blood</i> , 1996 , 87, 1520-31	2.2	17
109	Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, slg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. <i>Blood</i> , 1996 , 87, 1900-11	2.2	15

108	G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute leukemias. <i>Leukemia</i> , 1996 , 10, 860-5	10.7	10
107	Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma. <i>Haematologica</i> , 1996 , 81, 442-9	6.6	8
106	Visceral leishmaniasis during pregnancy treated with meglumine antimoniate. <i>Infection</i> , 1995 , 23, 182-3	5.8	15
105	All-trans retinoic acid and cyclic adenosine monophosphate cooperate in the expression of leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. <i>Blood</i> , 1995 , 85, 3619-3635	2.2	49
104	Constitutive expression of GATA-1, EPOR, alpha-globin, and gamma-globin genes in myeloid clonogenic cells from juvenile chronic myelocytic leukemia. <i>Blood</i> , 1995 , 86, 323-328	2.2	16
103	Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 1995 , 13, 935-41	2.2	43
102	Tyrosine kinases but not cAMP-dependent protein kinase mediate the induction of leukocyte alkaline phosphatase by granulocyte-colony-stimulating factor and retinoic acid in acute promyelocytic leukemia cells. <i>Biochemical and Biophysical Research Communications</i> , 1995 , 208, 846-54	3.4	13
101	Identification of chromosomal rearrangements in the human myeloid leukemia cell line GF-D8 by dual-colour fluorescence in situ hybridization. <i>Hematological Oncology</i> , 1995 , 13, 177-83	1.3	
100	Establishment of human acute myelogenous leukemia lines secreting interleukin-1 beta in SCID mice. <i>International Journal of Cancer</i> , 1995 , 61, 280-5	7.5	13
99	Adult polyomyositis/dermatomyositis associated with acute myeloid leukemia. A case report. <i>Clinical Rheumatology</i> , 1995 , 14, 217-9	3.9	7
98	Autologous PBSC transplant for late onset AML after mafosfamide-purged and TBI-containing autologous BMT. <i>Bone Marrow Transplantation</i> , 1995 , 15, 791-3	4.4	1
97	The use of anthracyclines in adult acute lymphoblastic leukemia. <i>Haematologica</i> , 1995 , 80, 280-91	6.6	10
96	All-trans retinoic acid and cyclic adenosine monophosphate cooperate in the expression of leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. <i>Blood</i> , 1995 , 85, 3619-35	2.2	3
95	Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. <i>Leukemia</i> , 1995 , 9, 238-43	10.7	21
94	Human monocytic leukemia expresses low levels of asparagine synthase and is potentially sensitive to L-asparaginase. <i>Leukemia</i> , 1995 , 9, 360-1	10.7	13
93	Prevalence of alcohol problems among adult somatic in-patients in Naples. <i>Alcohol and Alcoholism</i> , 1995 , 30, 441-8	3.5	3
92	Effects of dexamethasone on pro-inflammatory cytokine expression, cell growth and maturation during granulocytic differentiation of acute promyelocytic leukemia cells. <i>European Cytokine Network</i> , 1995 , 6, 157-65	3.3	18
91	Dissociation between p93B-myb and p75c-myb expression during the proliferation and differentiation of human myeloid cell lines. <i>Blood</i> , 1994 , 83, 1778-1790	2.2	21

90	Retinoic acid and granulocyte colony-stimulating factor synergistically induce leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. <i>Blood</i> , 1994 , 83, 1909-1921	2.2	70
89	Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 1994 , 330, 820-5	59.2	503
88	Determination of orally administered all-trans-retinoic acid in human plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1994 , 656, 239-44		13
87	Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia. <i>Stem Cells</i> , 1994 , 12, 394-401	5.8	11
86	Unexpected remission of acute myeloid leukaemia after GM-CSF. <i>British Journal of Haematology</i> , 1994 , 87, 835-8	4.5	12
85	Retinoic acid and granulocyte colony-stimulating factor synergistically induce leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. <i>Blood</i> , 1994 , 83, 1909-21	2.2	7
84	Expression of GATA-1 mRNA in human myeloid leukemic cells. <i>Leukemia</i> , 1994 , 8, 1034-8	10.7	11
83	Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. <i>Leukemia</i> , 1994 , 8, 156-9	10.7	33
82	Dissociation between p93B-myb and p75c-myb expression during the proliferation and differentiation of human myeloid cell lines. <i>Blood</i> , 1994 , 83, 1778-1790	2.2	2
81	Polymerase Chain Reaction Approach for the Evaluation of Minimal Residual Disease in Acute Leukemia. <i>Hamatologie Und Bluttransfusion</i> , 1994 , 9-14		
80	Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome. <i>Leukemia and Lymphoma</i> , 1993 , 11, 105-10	1.9	25
79	Clinical and biological effects of erythropoietin treatment of myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 1993 , 10, 127-34	1.9	4
78	Establishment and characterization of a new granulocyte-macrophage colony-stimulating factor-dependent and interleukin-3-dependent human acute myeloid leukemia cell line (GF-D8). <i>Blood</i> , 1993 , 81, 1376-1383	2.2	22
77	Detection of ALL-1/AF4 fusion transcript by reverse transcription- polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. <i>Blood</i> , 1993 , 82, 2943-2947	2.2	94
76	Interleukin-1 and glomerular mesangial cells. <i>Kidney and Blood Pressure Research</i> , 1993 , 16, 89-92	3.1	3
75	Reinforced HEAV'D therapy for adult acute lymphoblastic leukemia: improved results and revised prognostic criteria. <i>Hematological Oncology</i> , 1993 , 11, 169-77	1.3	9
74	Transcriptional and post-transcriptional regulation of IL-1 beta, IL-6 and TNF-alpha genes in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1993 , 83, 204-11	4.5	19
73	Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen. <i>Seminars in Oncology</i> , 1993 , 20, 39-46	5.5	13

72	Molecular genetics of the t(15;17) translocation in acute promyelocytic leukemia. <i>Recent Results in Cancer Research</i> , 1993 , 131, 345-59	1.5	
71	Procoagulant Cell Activities in Acute Leukemia. <i>Leukemia and Lymphoma</i> , 1992 , 7, 49-51	1.9	1
70	Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. <i>Lancet, The</i> , 1992 , 339, 1421	4.0	25
69	Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. <i>Lancet, The</i> , 1992 , 340, 1437-8	4.0	181
68	Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia.. <i>EMBO Journal</i> , 1992 , 11, 1397-1407	13	197
67	Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. <i>Blood</i> , 1992 , 80, 492-497	2.2	147
66	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. <i>Kidney International</i> , 1992 , 42, 981-90	9.9	17
65	Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1992 , 81, 628-30	4.5	11
64	Constitutive expression of IL-1 beta, M-CSF and c-fms during the myeloid blastic phase of chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1992 , 80, 310-6	4.5	9
63	Intensive retreatment of adults and children with acute lymphoblastic leukemia. <i>Hematological Oncology</i> , 1992 , 10, 105-10	1.3	6
62	Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. <i>Cancer</i> , 1992 , 69, 396-404	6.4	30
61	Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. <i>Cancer Research</i> , 1992 , 52, 2628-30	10.1	72
60	Interleukin-1 regulates cytokine gene expression in human mesangial cells through the interleukin-1 receptor type 1. <i>Journal of the American Society of Nephrology: JASN</i> , 1992 , 2, 1709-15	12.7	10
59	Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. <i>EMBO Journal</i> , 1992 , 11, 1397-407	13	68
58	Organ-specific growth of a murine lymphoma of spontaneous origin in nude mice. <i>Clinical and Experimental Metastasis</i> , 1991 , 9, 485-97	4.7	2
57	Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 1977-81	11.5	204
56	RAR-alpha gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia. <i>Blood</i> , 1991 , 77, 1418-1422	2.2	82
55	Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. <i>Blood</i> , 1991 , 77, 1657-1659	2.2	75

54	Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. <i>Blood</i> , 1991 , 78, 3248-3253 ^{2,2}	103
53	Monoclonal lymphocytosis with villous lymphocytes: a chronic lymphoproliferative disease of CD11c+ B-cells. <i>Leukemia</i> , 1991 , 5, 799-806	10.7 8
52	Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. <i>Blood</i> , 1991 , 78, 3248-53	2.2 23
51	Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. <i>Blood</i> , 1991 , 77, 1657-1659	2.2
50	Association of NK-cell lymphoproliferative disease and nephrotic syndrome. <i>American Journal of Clinical Pathology</i> , 1990 , 94, 334-8	1.9 15
49	Interleukin-1 and interleukin-2 control granulocyte- and granulocyte-macrophage colony-stimulating factor gene expression and cell proliferation in cultured acute myeloblastic leukemia. <i>International Journal of Cancer</i> , 1990 , 46, 902-7	7.5 14
48	Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. <i>Journal of Experimental Medicine</i> , 1990 , 172, 1571-5	16.6 169
47	Structure of the gene encoding the human leukocyte adhesion molecule-1 (TQ1, Leu-8) of lymphocytes and neutrophils. <i>Journal of Biological Chemistry</i> , 1990 , 265, 7760-7	5.4 68
46	A paracrine circuit in the regulation of the proliferation of macrophages infiltrating murine sarcomas. <i>Journal of Immunology</i> , 1990 , 144, 2409-12	5.3 39
45	Expression of leukocyte alkaline phosphatase gene in normal and leukemic cells: regulation of the transcript by granulocyte colony- stimulating factor. <i>Blood</i> , 1990 , 76, 2565-2571	2.2 36
44	Structure of the gene encoding the human leukocyte adhesion molecule-1 (TQ1, Leu-8) of lymphocytes and neutrophils.. <i>Journal of Biological Chemistry</i> , 1990 , 265, 7760-7767	5.4 70
43	Recombinant human interleukin 5 is a selective eosinophil chemoattractant. <i>European Journal of Immunology</i> , 1989 , 19, 701-5	6.1 278
42	Autoimmunity and B-cell dysfunction in chronic proliferative disorders of large granular lymphocytes/natural killer cells. <i>Cancer</i> , 1989 , 63, 90-5	6.4 54
41	Expression of c-jun protooncogene in human myelomonocytic cells. <i>Blood</i> , 1989 , 74, 1811-1816	2.2 40
40	Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. <i>Blood</i> , 1989 , 73, 1279-1284	94
39	Differences in the expression of alkaline phosphatase mRNA in chronic myelogenous leukemia and paroxysmal nocturnal hemoglobinuria polymorphonuclear leukocytes. <i>Blood</i> , 1989 , 73, 1113-1115	2.2 33
38	Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. <i>Journal of Immunology</i> , 1989 , 142, 139-43	5.3 47
37	Integrated use of morphology, cytochemistry, and immune marker analysis to identify acute leukaemia subtypes. <i>Haematologica</i> , 1989 , 74, 487-90	6.6 10

36	T cell receptor delta gene organization and expression in normal and leukemic natural killer cells. <i>Journal of Immunology</i> , 1989 , 143, 1009-14	5.3	13
35	Association of large granular lymphocyte/natural killer cell proliferative disease and second hematologic malignancy. <i>American Journal of Hematology</i> , 1988 , 29, 85-93	7.1	18
34	Investigation of chronic lymphocytosis in adults. <i>American Journal of Clinical Pathology</i> , 1988 , 89, 783-7	1.9	7
33	Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor- dependent mechanism. <i>Blood</i> , 1988 , 71, 672-676	2.2	170
32	Independent regulation of M-CSF and G-CSF gene expression in human monocytes. <i>Blood</i> , 1988 , 71, 1529-1532	2.1532	153
31	Induction of monocyte migration by recombinant macrophage colony-stimulating factor. <i>Journal of Immunology</i> , 1988 , 141, 575-9	5.3	146
30	Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. <i>Journal of Clinical Investigation</i> , 1988 , 81, 1030-5	15.9	94
29	c-sis but not c-fos gene expression is lineage specific in human myeloid cells. <i>Blood</i> , 1988 , 71, 488-493	2.2	
28	Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor- dependent mechanism. <i>Blood</i> , 1988 , 71, 672-676	2.2	
27	Independent regulation of M-CSF and G-CSF gene expression in human monocytes. <i>Blood</i> , 1988 , 71, 1529-1532	2.1532	1
26	Expression of the M-CSF (CSF-1) gene by human monocytes. <i>Blood</i> , 1987 , 69, 1409-1413	2.2	187
25	Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. <i>Blood</i> , 1987 , 70, 1218-1221	2.2	164
24	T-cell receptor gene rearrangements and expression in normal human large granular lymphocytes (LGL) and their pathological expansions. <i>Cytotechnology</i> , 1987 , 1, 79-81	2.2	
23	Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes. <i>European Journal of Immunology</i> , 1987 , 17, 153-6	6.1	47
22	T cell receptor (alpha, beta, gamma) gene rearrangements and expression in normal and leukemic large granular lymphocytes/natural killer cells. <i>Blood</i> , 1987 , 70, 1500-8	2.2	46
21	Expression of the M-CSF (CSF-1) gene by human monocytes. <i>Blood</i> , 1987 , 69, 1409-13	2.2	39
20	Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. <i>Journal of Clinical Investigation</i> , 1987 , 79, 1720-8	15.9	115
19	Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. <i>Blood</i> , 1987 , 70, 1218-1221	2.2	4

18	Large granular lymphocyte/natural killer cell proliferative disease: clinical and laboratory heterogeneity. <i>Scandinavian Journal of Haematology</i> , 1986 , 37, 91-6		16
17	Induction of cytotoxicity by interleukin-2 in T gamma-lymphoproliferative disorders. <i>International Journal of Cancer</i> , 1986 , 37, 27-33	7.5	14
16	Lymphokine production in T gamma lymphoproliferative disorders. <i>Scandinavian Journal of Immunology</i> , 1986 , 23, 183-8	3.4	9
15	Induction of monocyte-macrophage procoagulant activity by transformed cell lines. <i>Journal of Immunology</i> , 1986 , 136, 3848-55	5.3	17
14	Immunological and genotypic analysis of human T gamma-lymphoproliferative disorders. <i>Research in Clinic and Laboratory</i> , 1986 , 16, 29-35		2
13	Production of interleukin 1 but not of procoagulant activity by large granular lymphocytes. <i>Scandinavian Journal of Immunology</i> , 1985 , 22, 363-6	3.4	3
12	Intraperitoneal administration of interferon beta in ovarian cancer patients. <i>Cancer</i> , 1985 , 56, 294-301	6.4	54
11	T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells. <i>Journal of Experimental Medicine</i> , 1985 , 162, 2156-62	16.6	95
10	Study of the production of a strange ($S = \bar{1}$) dibaryon in the interactions of $K^{\bar{1}}$ and $\bar{\Lambda}$ on deuterium below 1.5 GeV/c. <i>Nuclear Physics B</i> , 1985 , 249, 172-188	2.8	35
9	Human mononuclear phagocytes from different anatomical sites differ in their capacity to metabolize arachidonic acid. <i>Clinical and Experimental Immunology</i> , 1984 , 57, 385-92	6.2	16
8	Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells. <i>British Journal of Cancer</i> , 1983 , 48, 515-25	8.7	25
7	Search for strange ($S = \bar{0}$) dibaryons in the reaction $K^{\bar{1}} d \rightarrow K^+ + MM$ at 1.4 GeV/c. <i>Nuclear Physics B</i> , 1982 , 209, 1-15	2.8	14
6	A missing-mass spectrometer for momenta below 1.5 GeV/c. <i>Nuclear Instruments & Methods in Physics Research</i> , 1981 , 188, 29-40		3
5	High resolution time-of-flight measurements in small and large scintillation counters. <i>Nuclear Instruments & Methods in Physics Research</i> , 1981 , 185, 49-65		16
4	Study of the missing-mass spectra in the reactions $\bar{\Lambda} \rightarrow K^+ + MM$ and $K^{\bar{1}} \rightarrow \bar{\Lambda} + MM$ at 1.4 GeV/c to search for strange dibaryon states. <i>Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics</i> , 1981 , 104, 330-334	4.2	9
3	Mass spectrum in the Q-Region of strange mesons produced in E_p Collisions at 6.15 GeV/c. <i>Lettere Al Nuovo Cimento Rivista Internazionale Della Societ� Italiana Di Fisica</i> , 1975 , 13, 265-268		1
2	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. <i>Leukemia</i> , 13 , 1901-1928	10.7	62
1	IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study		84

